
==== Front
NPJ Precis Oncol
NPJ Precis Oncol
NPJ Precision Oncology
2397-768X
Nature Publishing Group UK London

39266715
681
10.1038/s41698-024-00681-z
Review Article
Barriers and opportunities in pancreatic cancer immunotherapy
Ju Yixin 12
Xu Dongzhi 12
Liao Miao-miao 1
Sun Yutong 3
Bao Wen-dai 1
http://orcid.org/0000-0002-4393-7296
Yao Fan fyao@mail.hzau.edu.cn

124
http://orcid.org/0000-0001-9965-989X
Ma Li lma4@mdanderson.org

56
1 https://ror.org/023b72294 grid.35155.37 0000 0004 1790 4137 Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, Hubei 430070 China
2 grid.35155.37 0000 0004 1790 4137 Shenzhen Institute of Nutrition and Health, Huazhong Agricultural University, Shenzhen, Guangdong 518000 China
3 https://ror.org/04twxam07 grid.240145.6 0000 0001 2291 4776 Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
4 grid.410727.7 0000 0001 0526 1937 Shenzhen Branch, Guangdong Laboratory for Lingnan Modern Agriculture, Genome Analysis Laboratory of the Ministry of Agriculture, Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, Guangdong 518000 China
5 https://ror.org/04twxam07 grid.240145.6 0000 0001 2291 4776 Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 USA
6 https://ror.org/04twxam07 grid.240145.6 0000 0001 2291 4776 The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX 77030 USA
12 9 2024
12 9 2024
2024
8 1991 4 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Pancreatic ductal adenocarcinoma (PDAC) presents a fatal clinical challenge characterized by a dismal 5-year overall survival rate, primarily due to the lack of early diagnosis and limited therapeutic efficacy. Immunotherapy, a proven success in multiple cancers, has yet to demonstrate significant benefits in PDAC. Recent studies have revealed the immunosuppressive characteristics of the PDAC tumor microenvironment (TME), including immune cells with suppressive properties, desmoplastic stroma, microbiome influences, and PDAC-specific signaling pathways. In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, TME differences among various mouse models of pancreatic cancer, and the mechanisms underlying resistance to immunotherapeutic interventions. Furthermore, we discuss the potential of targeting cancer cell-intrinsic pathways and TME components to sensitize PDAC to immune therapies, providing insights into strategies and future perspectives to break through the barriers in improving pancreatic cancer treatment.

Subject terms

Cancer immunotherapy
Cancer
https://doi.org/10.13039/100000002 U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA166051 R01CA269140 Ma Li U.S. Department of Health & Human Services | National Institutes of Health (NIH)https://doi.org/10.13039/100000048 American Cancer Society (American Cancer Society, Inc.) DBG-22-161-01-MM Ma Li issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90% of pancreatic tumors, remains a formidable malignancy with a dismal 5-year survival rate of merely 12%1. More than 80% of patients are diagnosed at an advanced stage, either locally advanced or metastatic disease, rendering curative surgical intervention futile2,3. Although gemcitabine in combination with albumin-bound paclitaxel or modified FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) has been established as the standard first-line chemotherapeutic protocol for metastatic cases2, the clinical median survival still falls short of 1 year4,5.

Cancer immunotherapeutic approaches, including immune checkpoint blockade (ICB), chimeric antigen receptor (CAR) T-cell therapies, and cancer vaccines, have achieved significant advancements in treating various cancers6–8, such as melanoma, lung cancer, renal cell carcinoma, and lymphoma9–12. However, their effectiveness in PDAC remains disappointing6. Clinical studies utilizing immune checkpoint inhibitors (ICIs), including anti-programmed death ligand-1 (anti-PD-L1) or anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) mono-immunotherapy and combination therapy, have not been successful in treating pancreatic cancer13–15. In a recent phase 2 trial of metastatic PDAC, combining ICIs (durvalumab and tremelimumab) with chemotherapy (gemcitabine and nab-paclitaxel) did not improve survival compared with chemotherapy alone16.

The immunosuppressive tumor microenvironment (TME) in PDAC, a major factor contributing to immunotherapy resistance, includes tumor-infiltrating immune-suppressive cells, stromal cells, the microbiome, and the extracellular matrix (ECM). The immune infiltration in PDAC is characterized by an abundance of suppressive cells, a deficiency of anti-tumor immune cells, and immune dysfunction17–19. Exploring combination strategies involving immunotherapy and agents tailored to target these TME characteristics has emerged as a prominent area of research in pancreatic cancer.

In this article, we review recent advances in understanding the immunosuppressive TME of PDAC, describe TME differences among various animal models, discuss the mechanisms of immune resistance induced by TME and tumor cells, and summarize strategies aimed at improving the efficacy of immunotherapy in pancreatic cancer.

Highly immunosuppressive tumor microenvironment in PDAC

The TME of PDAC consists of various immune-suppressive cells, including immunosuppressive myeloid cells, M2 macrophages, N2 neutrophils, mast cells, Th2 cells, regulatory T cells, and regulatory B cells (Fig. 1 and Table 1). On the other hand, there is notable dysfunction and deficiency of anti-tumor immune cells, including CD8 + T cells, conventional dendritic cells, natural killer cells, M1 macrophages, N1 neutrophils, and Th1 cells (Fig. 1 and Table 2). The suppressive immune cells impede the cytotoxic T-cell-mediated tumor ablation effect, either directly or indirectly through inhibition of dendritic cells. In addition, the microbiome, stromal cells, and ECM modulate immune cell infiltration and function, contributing to the establishment of an immunosuppressive TME.Fig. 1 The immunosuppressive TME in PDAC.

a Schematic representation of the interplay among tumor cells, tumor-infiltrating immune cells, and cancer-associated fibroblasts (CAFs) in the PDAC TME. Tumor cells and CAFs secrete chemokines and growth factors, such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), CXCL2/5, and CXCL12 to recruit suppressive immune cells to tumor tissues. Pro-tumor immune cells contribute to the exhaustion of effector T cells and the activation of CAFs. Activated CAFs, in turn, support tumor growth through desmoplasia and inflammatory cytokines such as IL-6; in addition, they may cooperate with mast cells to promote tumor cell proliferation and metastasis. Upregulation of immune checkpoint molecules (e.g., PD-L1 and TIGIT) on tumor cells and immune cells, as well as downregulation of MHC-I, contribute to T-cell dysfunction. b Pro-tumor cells include myeloid-derived suppressor cells (MDSCs), M2 macrophages, N2 neutrophils, regulatory T cells, regulatory B cells, mast cells, and Th2 cells. Anti-tumor immune cells include CD8 + T cells, dendritic cells (DC), M1 macrophages, natural killer (NK) cells, N1 neutrophils, and Th1 cells.

Table 1 Pro-tumor immune cells in the PDAC TME

Cell type	Associated cells	Function/description	Molecule/signal	Reference	PMID	
Myeloid-derived suppressor cell (MDSC)	T cell	Inhibiting T-cell's anti-tumor activity and promoting immune evasion	PD-L1	Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer	27402485	
Arginase-1, xc- transporter	Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot & Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine	35839445

20028852

	
ROS, NO	Coordinated regulation of myeloid cells by tumors	22437938	
Tumor-associated macrophage (M2 macrophage)	T cell	Inhibiting T-cell response and supporting tumor growth	PD-L1, arginase-1	Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot	35839445	
TGF-β1, PD-L1	Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma	34862460	
Dectin-1, galectin-9	Dectin-1 Activation on Macrophages by Galectin-9 Promotes Pancreatic Carcinoma and Peritumoral Immune-Tolerance	28394331	
Receptor-interacting serine/threonine protein kinase 1 (RIP1)	RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer	30423296	
Cancer-associated fibroblast (CAF)	Inducing a pro-tumorigenic environment and fostering tumor cell survival and migration	Oncostatin M (OSM)	Heterocellular OSM-OSMR signaling reprograms fibroblasts to promote pancreatic cancer growth and metastasis	34921158	
IL-33, CXCL3	Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	33568427	
Tumor cell	Promoting tumor growth and metastasis	OSM, LOXL2	Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma	35428659	
TGF-β	(1) Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer (2) Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer	31199988

32341020

	
Lactobacillus,

CD8+ T cell

	Suppressing T-cell response and inducing tumor growth	AhR	Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity	35139353	
Tumor-associated neutrophil (N2 neutrophil)	T cell	Inducing neutrophil extracellular traps and excluding cytotoxic CD8+ T cells from tumors	IL17	Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer	32860704	
Effecting T-cell infiltration and promoting tumor metastasis	CXCR2	(1) CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma (2) CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma	27737879

27265504

	
Mast cell	CAF	Stimulating CAF proliferation and contributing to tumor development	IL-13, tryptase	Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer	20371681	
Tumor cell	Inducing cancer cell proliferation, migration, and invasion	Matrix metalloproteinase (MMP)	Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression	20371681	
Treg cell	Tumor cell	Migrating into the TME and exerting immunosuppressive effect via CCR5 signaling	CCR5	Disruption of CCR5-dependent homing of regulatory

T cells inhibits tumor growth in a murine model of pancreatic cancer

	19155524	
T cell	Inhibiting CD8+ T-cell response and eliciting T-cell exhaustion	CTLA-4, PD-1, TIGIT	Mechanisms of T-Cell Exhaustion in Pancreatic Cancer	32823814	
IL-10, TGF-β	Mechanisms of T-Cell Exhaustion in Pancreatic Cancer	32823814	
Th2 cell	Tumor cell	Promoting tumor progression and decreasing survival	TH2 cytokines	(1) A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma (2) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer	28932629

21339327

	
Breg cell	T cell,

NK cell

	Reducing the proliferation of NK cells and attenuating

T cell- and NK cell-mediated anti-tumor responses

	IL-18, IL-10, PD-1	Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway	29599908	
STING, IL-35	STING-induced regulatory B cells compromise NK function in cancer immunity	36198789	
T cell	Inhibiting T-cell infiltration and anti-tumor immunity	IL-35, BCL6	Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity	36099917	
B-cell receptor (BCR), protein kinase D2 (PKD2), IL-35	B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer	35046933	
IL-35, STAT3	B-cell-derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer	32024640	
IL-1β, IL-35, PD-L1	Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression	32393543	
TAMs, T cell	Inducing T(H)2-type macrophage programming and suppressing CD8+ T-cell-mediated cytotoxicity	Bruton tyrosine kinase (BTK)	(1) Bruton’s Tyrosine Kinase (BTK)-dependent immune cell crosstalk drives pancreas cancer (2) BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis	26715645

30635655

	
LOXL2 lysyl oxidase-like protein 2, AhR aryl hydrocarbon receptor, TIGIT T-cell immunoreceptor with Ig and ITIM domains, STING stimulator of interferon genes.

Table 2 Anti-tumor immune cells in the PDAC TME

Cell types	Associated cells	Function/Description	Molecular/signal	Reference	PMID	
NK cell	Tumor cell	NK cell killing function is inhibited by oncoprotein signaling	SKI, ligand for cytotoxicity receptor (NKG2D-L)	The oncoprotein SKI acts as a suppressor of NK cell-mediated immunosurveillance in PDAC	33023028	
Unknown	Defective NK cell expansion, cytotoxicity, and lack of ability to differentiate tumors from a pancreatic cancer patient in a long-term follow-up: implication in the progression of cancer	34559307	
Polysaccharide activates NK cells by upregulating NKG2D	Polysaccharide, TLR4/MAPKs/NF-κB	Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo	31521276	
CD8+ T cell	Macrophage	Producing lymphotoxin that reprograms macrophages to be tumoricidal	Lymphotoxin	cIAP1/2 antagonism eliminates MHC class I-negative tumors through T-cell-dependent reprogramming of mononuclear phagocytes	34011631	
Th1 cell	CD8+T cell	Inducing cytotoxic CD8+ T cells through T-bet and IFN-γ	T-bet, IFN-γ	Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis	33188035	
Dendritic cell	T cell	Critical for T-cell priming while exhibiting paucity and dysregulation in PDAC	MHC-2, CD80/86, CD40, FLT3	(1) Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis

(2) Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer

(3) Paucity of dendritic cells in pancreatic cancer

(4) Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells

	32453421

32183949

11854690

16920987

	
M1 macrophage (tumoricidal macrophage)	Tumor cell	Activating tumoricidal M1 macrophages and altering tumor stroma	CD40	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans	21436454	
N1 neutrophil	CD8+ T cell, Treg cell	Enhancing CD8+ T-cell infiltration and inhibiting Treg cells	Unknown	Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma	36600557	
Tumor cell	Inhibiting tumor growth and metastasis	Neutrophil elastase	Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis	33964209	
FLT3 fms-like tyrosine kinase 3.

Immunosuppressive myeloid cells

Suppressive myeloid cells in the TME can be broadly categorized into myeloid-derived suppressor cells (MDSCs) comprising granulocytic MDSCs and monocytic MDSCs, tumor-associated macrophages (TAMs) derived from either the bone marrow or resident tissue macrophages6,20, tumor-associated neutrophils (TANs), and mast cells. These myeloid cells are recruited to the TME by various factors and attenuate anti-tumor T-cell responses in PDAC21,22.

MDSCs

MDSCs are a subset of anti-inflammatory, immunosuppressive cells, originating from immature myeloid cells under various pathological conditions such as chronic inflammation, cancer, and autoimmune disease23. In pancreatic cancer, MDSCs exert immunosuppressive functions and promote immune evasion through EGFR-MAPK-dependent upregulation of PD-L1 expression in tumor cells24. It has also been reported that MDSCs deplete nutrition through arginase-1 and the Xc- transporter, resulting in the downregulation of the T-cell receptor (TCR) and restriction of T-cell activation6,25. In addition, MDSCs can promote regulatory T (Treg) cell induction in a cell-cell-dependent manner26,27. In an autochthonous PDAC model, depletion of granulocytic MDSCs elevated CD8 + T-cell infiltration and increased tumor cell apoptosis28. Moreover, reducing MDSCs through loss or inhibition of CXCR2 mitigated tumor metastasis and conferred sensitivity to anti-PD-1 therapy, thus prolonging survival in mice with pancreatic cancer29. Notably, a recent preclinical study by DePinho and colleagues30 demonstrated that inhibition of chemokine receptors on MDSCs (by using a CXCR1/2 inhibitor) combined with modulation of T-cell immune checkpoints (by using a 41BB agonist and a LAG3 antagonist) could reprogram the highly suppressive tumor immune microenvironment of pancreatic cancer. This approach led to durable responses and survival benefits in a mouse model of PDAC, suggesting a potential clinical strategy.

TAMs

TAMs in the PDAC TME are characterized by an enrichment of pro-tumor M2-like phenotypes and a relatively low presence of anti-tumor M1-like phenotypes19. The immune suppression mediated by these pro-tumor TAMs stems from their ability to hamper the anti-tumor activity of CD8+ cytotoxic T lymphocytes by supporting PD-L1 expression in tumor cells and depleting nutrition in T cells24,27,31. Moreover, TAMs hinder adaptive immune responses through the dectin-1/galectin-9 axis32 and facilitate the production of immunosuppressive factors in tumor cells, such as CXCL1 and CXCL5, through elevated expression of apolipoprotein E (ApoE)33.

In PDAC models, reprogramming TAMs through the blockade of receptor-interacting serine/threonine protein kinase 1 (RIP1) leads to activation of cytotoxic T cells and differentiation of T helper (Th) cells into a mixed Th1/Th17 phenotype34. Previous studies have revealed the pro-tumor effects of Th2 cells and the anti-tumor effects of Th1 cells34,35. While the precise function of combined Th1/Th17 phenotypes remains to be defined in tumors, they appear to possess significant immunogenicity and are associated with the downregulation of FOXP3, a biomarker of Treg cells34. Interestingly, an exosome-based dual delivery biosystem, featuring electroporation-loaded galectin-9 siRNA and surface modification with an oxaliplatin prodrug, effectively reversed M2-like phenotypes of TAMs and enhanced anti-tumor immunity in mice36. In addition to their role in immune suppression, TAMs support cancer cells by secreting growth factors such as TGF-β37,38 and producing cytokines and chemokines that accelerate tumor metastasis directly or indirectly39–41.

A study comparing immune infiltrates in pancreatic cancer and melanoma identified VISTA (V-domain immunoglobulin suppressor of T-cell activation) as a potential immune checkpoint primarily expressed on CD68+ macrophages in PDAC42. Targeting VISTA-positive macrophages holds promise as a strategy to augment CD8 + T-cell responses and treat pancreatic cancer. Furthermore, a recent preclinical study demonstrated that dual antagonism of CCR2 and CCR5 (CCR2/5i), when combined with radiation therapy and an anti-PD-1 antibody, resulted in a reduction in tumor infiltration by Tregs, M2-like TAMs, and MDSCs43. Notably, this combination treatment increased intratumoral effector and memory T cells, supporting the clinical development of CCR2/5i in combination with radiation therapy and ICB for the treatment of PDAC.

TANs

Neutrophils are major players in innate immunity. A single-cell RNA-seq (scRNA-seq) analysis uncovered a terminally differentiated subpopulation of TANs exhibiting hyperactivated glycolysis and pro-tumor functions in PDAC, which is associated with unfavorable prognosis in patients44. Pro-tumor neutrophils secrete immunosuppressive cytokines and chemokines, thereby inhibiting the activity of cytotoxic CD8 + T cells45. Moreover, neutrophil extracellular traps (NETs) have been reported to contribute to immunotherapy resistance induced by TANs. One of the inducers of NETs, IL17, which is upregulated in PDAC, recruits neutrophils while excluding cytotoxic CD8 + T cells from tumors46. In preclinical mouse models, targeting TANs with lorlatinib has been shown to enhance the response to PD-1 blockade, highlighting the potential of modulating pro-tumor neutrophils in the TME as a treatment strategy for PDAC47.

Aside from primary tolerance, the replenishment of TANs is a contributing factor to therapy resistance in pancreatic cancer. Targeting CCR2+ macrophages led to a compensatory influx of CXCR2+ TANs, a phenomenon associated with poor outcomes in PDAC patients; interestingly, dual inhibition of CCR2+ TAMs and CXCR2+ TANs significantly improved anti-tumor immunity and chemotherapeutic responses in orthotopic models of PDAC48. Similar to the plasticity of TAMs, recent studies have revealed the plasticity of TANs—the presence of both N1 and N2 phenotypes in the TME of PDAC patients. The N1/N2 ratios positively correlated with CD8 + T-cell infiltration, median overall survival (OS), and recurrence-free survival, and inversely correlated with the abundance of tumor-infiltrating Tregs49. In mouse models of PDAC, blockade of the TGF-β1 receptor promoted the polarization of neutrophils into an anti-tumor N1 phenotype, thus enhancing the response of tumors to the combination treatment with irreversible electroporation (which ablates tumors by inducing irreversible membrane destruction of cells) and anti-PD-150.

Mast cells

Mast cells, like neutrophils and macrophages, originate from myeloid progenitor cells. Compared with normal tissues, PDAC tissues exhibit a significant increase in infiltration by mast cells, which promote the proliferation and invasion of pancreatic cancer cells and contribute to chemotherapy resistance51–54. The exact role and mechanisms by which mast cells regulate tumor immunity in PDAC are not fully understood. Nevertheless, it is worth noting that in preclinical models of melanoma, combining anti-PD-1 therapy with the depletion of mast cells resulted in tumor regression55, suggesting that mast cells may suppress the immune response and limit the efficacy of immunotherapies.

Treg cells

Treg cells are a specialized subset of T cells that modulate effector T cells. The abundance of FOXP3+ Treg cells within pancreatic tumors increases during PDAC progression and correlates with poor survival56–58. The immunomodulatory effect of Treg cells has been studied in different models59,60. Bar-Sagi and colleagues61 reported that Treg cells inhibit the function of dendritic cells through direct contact, leading to the downregulation of dendritic cell-derived costimulatory ligands that are crucial for CD8 + T-cell activation in PDAC. This study also demonstrated that the elimination of Treg cells induced an effective anti-tumor immune response in mice bearing orthotopic pancreatic tumors derived from a KPC model (expressing mutant forms of Kras and Trp53)61. On the other hand, however, Pasca di Magliano and colleagues62 reported that the removal of Treg cells accelerated tumor progression by reprogramming cancer-associated fibroblasts in genetically engineered mouse models of PDAC. The conflicting results from orthotopic and autochthonous models indicate context-dependent crosstalk between Tregs and other cell types in pancreatic cancer TME.

B cells

Plasma cells, a subtype of terminally differentiated B cells, play an essential role in amplifying anti-tumor immune responses through antibody production. However, in PDAC patients and tumor-bearing mice, cancer can induce differentiation of naïve B cells into regulatory B cells (as opposed to plasma cells) through Bruton tyrosine kinase (BTK) signaling, which results in a reduction in tumor-infiltrating cytotoxic T cells, thereby contributing to immune evasion63,64. In addition, BTK induces the programming of T(H)2-type macrophages and diminishes CD8 + T-cell cytotoxicity by facilitating the communication between B cells and TAMs in PDAC65. Furthermore, extensive research has advanced the understanding of the mechanisms of immunosuppression induced by B cells and IL-3563,66–69. Targeting B cells through molecular blockade has shown promise in reducing tumor growth and disease progression, presenting a therapeutic strategy for treating PDAC in combination with immunotherapy63–65,68–71.

Stromal cells and extracellular matrix (ECM)

PDAC is characterized by extensive desmoplasia, where fibroblasts are the major cell type72. A subset of fibroblasts (myofibroblasts), along with tumor cells and macrophages, can produce a dense fibrotic matrix composed of ECM proteins, thereby influencing the progression of PDAC and its response to treatment73–75. The excessive desmoplastic stroma limits the penetration of tumors by drugs and cytotoxic CD8 + T cells76. Addressing this challenge, enzymatic degradation of hyaluronic acid (HA) has been shown to alleviate desmoplastic pressure. This approach not only expands the microvasculature but also contributes to a 2-fold increase in overall survival in mouse models when combined with chemotherapy77,78. In human PDAC tissues, elevated focal adhesion kinase (FAK) activity correlates with increased fibrosis and poor CD8 + T-cell infiltration79. Treatment with a FAK inhibitor led to a reduction in fibrosis and tumor-associated immunosuppressive cells, sensitizing the p48-Cre;LSL-KrasG12D/+;Trp53flox/+ mouse model of PDAC to T-cell immunotherapy and immune checkpoint inhibitors79. Furthermore, combining HA degradation with FAK inhibition promoted the survival of PDAC-bearing mice treated with an anti-PD-1 antibody80; notably, this combination treatment enhanced T-cell infiltration while concurrently reducing MDSCs.

Besides producing dense ECM, CAFs interact with immune cells and induce immune suppression through secreted factors such as IL-6, CXCL12, granulocyte-macrophage colony-stimulating factor (GM-CSF), and macrophage colony-stimulating factor (M-CSF)81,82. The removal of CAFs expressing fibroblast activation protein (FAP) has been shown to inhibit tumor growth and enhance the efficacy of anti-CTLA-4 and anti-PD-L1 antibodies in mouse models of PDAC83. On the other hand, however, depletion of alpha smooth muscle actin (αSMA)-positive CAFs hampers immune surveillance, leading to an increase in Treg cells and shorter survival in mice with PDAC84. Taken together with other studies73,74,85–87, these findings underscore the functional heterogeneity of CAFs. CAFs can be classified into inflammatory CAFs (iCAFs), αSMA + myofibroblasts (myCAFs), and antigen-presenting CAFs (apCAFs), with a small subset of CAFs being derived from pancreatic stellate cells74,87,88. While apCAFs support immune evasion by inducing expansion of Treg cells89, the pro-tumor role of iCAFs is associated with the cytokine IL-6, which suppresses anti-tumor immunity by eliciting metabolic stress and dendritic cell apoptosis90,91. Moreover, induction of iCAFs by IL-17A-producing CD8 + T cells promotes PDAC progression and is associated with a poor prognosis92. myCAFs are the major source of type I collagen in the PDAC stroma, and depletion of type I collagen leads to upregulation of Cxcl5 in tumor cells, which promotes the recruitment of MDSCs and dysfunction of CD8 + T cells, thereby accelerating pancreatic cancer progression and decreasing survival93. Intriguingly, whereas intact type I collagen triggers degradation of discoidin domain receptor 1 (DDR1) and impedes PDAC, matrix-metalloprotease-cleaved type I collagen promotes PDAC growth by activating the DDR1–NF-κB–NRF2 axis94.

Stroma-modulating drugs have shown the potential to enhance the efficacy of ICB therapy in preclinical models of PDAC. For instance, combination treatment with the sonic hedgehog inhibitor cyclopamine and the chemotherapeutic drug paclitaxel increased the infiltration of CD8 + T cells into tumors. A synergistic effect of this combination with anti-PD-1 therapy was observed in both orthotopic and genetically engineered mouse models of PDAC76. More recently, the combination of MEK inhibitor (MEKi) with STAT3 inhibitor (STAT3i) demonstrated promising results in mitigating the polarization of iCAFs and enriching CAFs with mesenchymal stem cell-like features. The resulting stroma remodeling facilitated the M2-to-M1 reprogramming of TAMs, improved the trafficking of CD8 + T cells, and impeded the infiltration of myeloid cells95. When the MEKi + STAT3i combination was added to anti-PD-1 treatment, prolonged survival was observed in PDAC-bearing mice compared with anti-PD-1 treatment alone. These findings suggest that targeting the stromal components holds promise as a strategy to overcome immunotherapy resistance in PDAC. The exploration of stroma-modulating drugs in combination with immunotherapies may pave the way for improved treatment outcomes.

Microbiome

Recent studies have implicated the microbiome in the pathogenesis and immune suppression in PDAC96,97. The gut microbiome can translocate into pancreatic cancer tissues, modulating the tumor microbiome and altering the immune landscape of TME97,98 (Fig. 2). Ablation of the gut microbiome by oral antibiotics has been shown to reverse the immunosuppressive TME. This reversal is characterized by an increase in anti-tumor interferon-γ-producing T cells, Th1 cells, and M1 macrophages, as well as a decrease in pro-tumor IL-17a- and IL-10-producing T cells and MDSCs, thereby enhancing the efficacy of ICB therapy97,99. Moreover, fungus-dependent IL-33 secretion by PDAC cells plays a role in recruiting and activating Th2 cells and innate lymphoid cells 2 (ILC2)100; these cells, in turn, contribute to immune suppression by secreting pro-tumorigenic cytokines. In addition, pathogenic fungi can promote PDAC progression via a mannose-binding lectin (MBL)–C3 axis96. It has also been reported that compared with healthy individuals, Proteobacteria, Synergistetes, and Euryarchaeota are enriched in PDAC patients, reprograming TAMs toward a pro-tumor M2-like phenotype through Toll-like receptor (TLR) signaling97. Intriguingly, Lactobacillus metabolization of dietary tryptophan fosters TAM polarization toward an immune-suppressive phenotype through the aryl hydrocarbon receptor, accelerating PDAC progression101.Fig. 2 The microbiome associated with immune suppression in PDAC TME.

a Intratumoral fungus-mediated IL-33 secretion by PDAC cells recruits and activates Th2 cells and innate lymphoid cells 2 (ILC2), which stimulate tumor growth by secreting pro-tumorigenic cytokines such as IL-4, IL-5, and IL-13. b Pathogenic fungi promote PDAC progression by driving the complement cascade via a mannose-binding lectin (MBL)–C3 axis. c Proteobacteria, Synergistetes, and Euryarchaeota are enriched in PDAC patients, reprogramming TAM toward a pro-tumor M2-like phenotype through Toll-like receptors (TLRs). (d) Lactobacillus-derived indole fosters TAM polarization toward an immune-suppressive phenotype through the aryl hydrocarbon receptor (AhR). Figure created with BioRender.com.

Collectively, these findings highlight the complex relationship between the microbiome and the immune response in PDAC, opening up potential avenues for therapeutic interventions. For instance, the delivery of gut microbiome-derived metabolite trimethylamine N-oxide (TMAO) has been shown to enhance anti-tumor immunity and restrain tumor growth in orthotopic models of PDAC. When combined with anti-PD-1 therapy, TMAO delivery led to a significant reduction in tumor burden and prolonged survival compared with treatment with TMAO or ICB alone102. In a study led by McAllister and colleagues98, analysis of the tumor microbiome in PDAC patients by using 16S rRNA gene sequencing revealed higher microbial diversity in patients with longer survival. Notably, human-to-mice fecal microbiota transplants from control, long-term survival, or short-term survival donors differentially modulated the tumor microbiome, tumor growth, and tumor immune infiltration98. Furthermore, a metagenomic analysis uncovered specific microbiome species associated with PDAC, including enrichment of Streptococcus and Veillonella spp and depletion of Faecalibacterium prausnitzii103. This study suggests that microorganisms could serve as potential sources of biomarkers for pancreatic cancer. It should be noted that recent re-analyses of previously reported pan-cancer microbial composition data have identified significant pitfalls, including contamination, false positive classifications, problematic handling of batch effects, and limitations in the machine learning approaches used104, which warrant corrections and future improvement.

Immune features of PDAC metastases

The liver and lung are the common sites of metastasis in patients with PDAC105,106. In general, patients with liver metastases have a poorer prognosis compared with those with lung metastases, indicating inherent disparities between these metastatic sites105,106. In mouse models of metastatic PDAC, significant differences were observed in the TME between the liver and the lung: whereas the liver exhibited immunosuppressive characteristics, the lung TME showed high levels of immune infiltration and activated immune signaling105. Using cytometry by time-of-flight, Jaffee, Fertig, and colleagues analyzed a mouse model of metastatic PDAC and found a reduction in dendritic cells, NK cells, cytotoxic T cells, and Th cells in the TME of liver metastases relative to those present in lung metastases105. Moreover, significant enrichment of PD-L1 and LAG3 was observed in the hepatic TME, along with higher levels of pro-tumorigenic chemokines such as CCL5, CCL22, and CXCL12 relative to the lung. In contrast, immune-activating chemokines, such as CXCL9 and CXCL10, were found to be enriched in lung metastases relative to liver metastases105.

A recent investigation of patient samples revealed significant immune heterogeneity in PDAC recurrences across various sites including the liver, lung, peritoneum, and local areas106. This study demonstrated low immunogenicity, stemness, and innate immune responses in patients with liver and/or peritoneal recurrences, contrasting with notable interferon-γ signaling and mixed adaptive and innate immune responses in PDACs with local and/or lung recurrences. In addition, accumulation of P2RX1-negative neutrophils was found in PDAC liver metastases, alongside various suppressive cells such as macrophages and fibroblasts, which promote metastatic progression in the liver107–109. Furthermore, JAK-STAT–dependent macrophage-fibroblast crosstalk was reported to facilitate liver metastatic outgrowth in PDAC. Notably, pharmacological inhibition of STAT3 or myofibroblastic metastasis-associated fibroblast (myMAF)-specific genetic depletion of STAT3 restored anti-tumor immunity and reduced liver metastases109.

TME differences among various mouse models of pancreatic cancer

Patient-derived xenograft (PDX) models, syngeneic mouse models, and genetically engineered mouse models (GEMMs) are widely used in pancreatic cancer research and preclinical drug testing110. It is important to recognize that these models exhibit distinct TMEs, necessitating careful selection based on the specific experimental objectives in preclinical studies. Moreover, there is a critical need to emphasize comparative validation across multiple models to ensure the robustness and reproducibility of findings.

Cell line-derived xenograft and PDX models of pancreatic cancer are widely used for gene function studies and evaluation of therapeutic approaches111. These models are categorized based on the implantation site into orthotopic and subcutaneous models. Subcutaneous models facilitate non-surgical implantation of tumor cells or tissue fragments, whereas orthotopic models, despite being more technically challenging to establish, better recapitulate tumor growth in the natural tissue microenvironment compared with subcutaneous models. It is important to note that PDX models require immunodeficient mice (typically nude mice, SCID mice, or NOD-SCID mice) to prevent immune rejection of human-derived xenografts. However, this immunodeficiency limits their utility for studying the immune cell composition of tumors or evaluating immunotherapy efficacy. Addressing this limitation, humanized mouse models have been developed for immunotherapy studies. For example, Chang and colleagues112 isolated CD34+ hematopoietic stem cells from human umbilical cord blood and injected them into 3- to 4-week-old NSG mice to establish a humanized model. Treatment with siRNA nanoparticles targeting PD-L1 upregulated interferon-γ-positive CD8 + T cells and inhibited pancreatic tumor growth in this model, underscoring the potential of humanized PDAC PDX models for advancing immunotherapy research.

Syngeneic mouse models of PDAC involve implanting immunologically compatible cancer cells or tissues into mice with an intact immune system, which distinguishes them from xenograft models. These models can also be established through subcutaneous or orthotopic implantation110. Orthotopic tumors actively interact with the tissue microenvironment, providing a more physiologically relevant model. However, due to the technical challenges associated with orthotopic models, subcutaneous models remain commonly used in preclinical drug trials. It should be noted that cell line- or model-dependent effects are often observed. For example, in a study investigating the potential of a CD47 monoclonal antibody to enhance the response of PDAC to ICIs, combination therapy targeting CD47 and PD-L1 showed synergistic inhibition of tumor growth in the Panc02 but not in the MPC-83 syngeneic mouse model113. This indicates that treatment responses may vary between models derived from different PDAC cell lines. scRNA-seq analysis revealed that anti-CD47 treatment reshaped the intratumoral lymphocyte and macrophage populations in Panc02 tumor-bearing mice, resulting in increased intratumoral CD8 + T cells, more active T-cell clusters, enhanced anti-tumor pro-inflammatory macrophages, and reduced anti-inflammatory macrophages113. These findings underscore the suitability of specific syngeneic models with intact immune systems for investigating the intratumoral immune microenvironment and conducting preclinical trials of immunotherapy.

GEMMs allow immunocompetent mice to spontaneously develop pancreatic cancer, eliminating the need for exogenous implantation methods. They have become indispensable for evaluating various therapeutic strategies111. Among these models, the LSL-KrasG12D/+;Trp53flox/flox;Pdx-1-Cre (KPC) model is a commonly used GEMM capable of generating spontaneous pancreatic tumors that closely mimic human PDAC, with features including prominent connective tissue hyperplasia, abnormal vascular distribution, and high metastatic potential. These tumors also exhibit extensive infiltration of immunosuppressive macrophages and low numbers of effector T cells110. Studies on KPC mice have demonstrated that CD40 activation induces tumor regression through a T-cell-independent mechanism. This finding aligns with histological analyses of human tumors treated with a combination of CD40 agonists and gemcitabine. However, these results differ from those observed in the implantable KPC model114,115, suggesting that GEMMs may be more similar to humans in terms of the TME and the mechanisms of immunotherapy response. This highlights the importance of model selection.

In conclusion, various PDAC mouse models exhibit significant differences in TME and response to immunotherapy. For preclinical experiments, selecting models with intact immune function, tumor pathological features, and microenvironments similar to those of humans is important for studying pancreatic carcinogenesis, metastasis, and immunotherapeutic strategies.

Pancreatic cancer cell-intrinsic factors contributing to immunotherapy resistance

In addition to the immunosuppressive TME of PDAC cells, tumor-intrinsic features also contribute to immune evasion (Fig. 3). KRAS mutations are present in more than 95% of PDAC116, among which the major mutations are G12D (40%), G12V (33%), and G12R (15%)117 (Fig. 3a). Downstream signaling pathways and metabolic networks in mutant KRAS (mKRAS)-driven tumors play a pivotal role in immune suppression and tumor progression116,117. For instance, mKRAS leads to upregulation of CXCL1, CXCL5, and GM-CSF through NF-κB, PI-3K, or MAPK pathways, fostering the proliferation, maturation, and recruitment of immunosuppressive myeloid cells33,118,119. Moreover, mKRAS boosts PD-L1 expression on tumor cells through p38 and MAPK pathways, thereby activating the PD-1/PD-L1 checkpoint and causing T-cell exhaustion24,120. In addition, mKRAS modulates the tumor cell metabolism, increasing glucose uptake, and aerobic glycolysis, as well as the production of reactive oxygen species (ROS)121,122. ROS, in turn, mediates mKRAS-induced PD-L1 expression through FGFR1 signaling122. It has also been shown that mKRAS recruits immunosuppressive IL-17-producing T cells35 and promotes the formation and maintenance of fibro-inflammatory stroma123.Fig. 3 Tumor-intrinsic signaling pathways associated with immune evasion in PDAC.

a Mutated KRAS (mKRAS), which is permanently bound to GTP, constitutively activates downstream signaling pathways, resulting in PD-L1 overexpression and the recruitment of immunosuppressive cells to pancreatic tumors. b Aberrant activation of the WNT–β-catenin pathway, which can be caused by mutation of RNF43 or lncRNA-mediated inhibition of β-catenin degradation, reduces dendritic cell recruitment by downregulating CCL4 and upregulating PD-L1 expression. c Lipophilic glucocorticoids (GCs) diffuse through the cell membrane and bind to the glucocorticoid receptor (GR) in the cytoplasm of PDAC cells. This binding induces a change in the chaperone complex bound to GR, leading to its translocation into the nucleus. Once in the nucleus, GR activates PD-L1 expression and represses MHC-1 expression by binding to glucocorticoid response elements (GREs), ultimately leading to the reduction in the abundance and effector function of tumor-infiltrating CD8 + T cells.

Activation of WNT signaling is often observed in pancreatic cancer124,125 (Fig. 3b). In PDAC, WNT pathway activation is associated with the aberrant expression of WNT ligands. Moreover, a subset of PDAC tumors carry mutations in RNF43, which encodes ring finger 43, a ubiquitin ligase that inhibits WNT signaling by ubiquitinating FZD receptors and LRP5/6 co-receptors, leading to their internalization and lysosomal degradation126,127. The loss of RNF43 in a genetically engineered mouse model of PDAC accelerated tumor progression and upregulated regulatory T-cell immune checkpoint molecules, which could be a potential mechanism of immune evasion128. In addition, lncRNA-mediated inhibition of β-catenin degradation has been observed in pancreatic cancer cells129,130. Although current evidence indicates that WNT pathway activation is immunosuppressive in PDAC, the role of WNT–β-catenin signaling in regulating cancer immunosurveillance may be cancer-type-dependent131.

In addition to KRAS mutation and RNF43 loss, downregulation of major histocompatibility complex class I (MHC-I) contributes to immune evasion and immunotherapy resistance due to impaired antigen presentation. Kimmelman and colleagues132 demonstrated that in pancreatic cancer cells, an autophagy-dependent mechanism, involving the autophagy cargo receptor NBR1, targets MHC-I molecules for lysosomal degradation. A subsequent study revealed that progranulin from tumor cells (not macrophages) correlates with poor overall survival in PDAC. Inhibition of progranulin effectively halted autophagy-dependent degradation of MHC-I and restored MHC-I expression in pancreatic cancer cells. Moreover, antibody-based progranulin blockade in a mouse model of PDAC impeded the initiation and progression of tumors133. Glucocorticoid receptor (GR) signaling was thought to suppress immunity by acting on immune cells134. In a recent study, our laboratory uncovered a new role of GR as a transcriptional activator of PD-L1 and a transcriptional repressor of MHC-I in pancreatic cancer cells135 (Fig. 3c). In preclinical models, either genetic depletion or pharmacological inhibition of GR promoted the infiltration and effector function of cytotoxic T cells, leading to enhanced immune surveillance and sensitization of pancreatic tumors to ICIs135. These findings highlight GR signaling in pancreatic cancer cells as a tumor-intrinsic mechanism of immune suppression and suggest that therapeutic intervention targeting GR holds promise for improving the responsiveness of pancreatic cancer to immunotherapy. Furthermore, it should be noted that p53, which is frequently altered in PDAC, has been shown to promote antigen processing and MHC-1 surface expression136,137. Both aspects of antigen presentation are downregulated in p53-null and p53-mutant cancer cells136,137.

Metabolic enzymes have crucial roles in multiple aspects of cancer, including tumorigenesis, progression, metastasis, and therapy resistance. Recently, Sherman and colleagues138 reported that pancreatic cancer cell-intrinsic glutamic-oxaloacetic transaminase 2 (GOT2), a key player in the malate-aspartate shuttle, remodels TME to suppress anticancer immunity138. Mechanistically, GOT2 promotes the transcriptional activity of nuclear receptor peroxisome proliferator-activated receptor delta (PPARδ) to restrict CD4+ and CD8 + T-cell infiltration of the TME, revealing a non-canonical function for this metabolic enzyme138. Moreover, Zhang and colleagues139 showed that deficiency in quinoid dihydropteridine reductase orchestrates a series of events culminating in the recruitment of MDSCs, which ultimately induce immunosuppression in PDAC. In addition, pancreatic cancer cells can impair NK cell activity by competitively depleting vitamin B6, thereby compromising anti-tumor immunity140. Interestingly, metabolism-focused CRISPR screens have identified genes linked to immune evasion in PDAC, including Tap1, Tapbp, and the autophagy gene Atg7141. Furthermore, tumor cell-intrinsic deficiency in the epigenetic regulator SETD2 has been shown to promote tumor progression through two mechanisms: 1) by enhancing mitochondrial oxidative phosphorylation through interactions with a subset of lipid-rich CAFs142, and 2) by boosting recruitment of immunosuppressive neutrophils through activation of the PI3K-AKT pathway143.

Reprogramming cancer microbiome has been linked to immune evasion, particularly in PDAC. The collagen I (Col1) homotrimer produced by pancreatic cancer cells fosters oncogenic signaling by binding to α3β1 integrin, resulting in the development of a tumor microbiome abundant in anaerobic Bacteroidales in hypoxic and immunosuppressive TME144. Deleting Col1 homotrimers in a mouse model of PDAC yielded significant benefits, including increased overall survival, enhanced T-cell infiltration, and improved responsiveness to anti-PD-1 immunotherapy144.

Therapeutic strategies and clinical trials of pancreatic cancer immunotherapies

Despite a number of breakthroughs in immunotherapies for multiple cancer types, their clinical utility in PDAC, whether administered as monotherapy or in combination with other therapies, has been insufficient. Nevertheless, extensive preclinical studies and clinical trials have provided valuable insights. In this section, we discuss three types of immunotherapeutic strategies for pancreatic cancer treatment (Table 3): (i) targeting myeloid cells, dendritic cells, or B cells to enhance T-cell trafficking and anti-tumor responses; (ii) reprogramming macrophages to be tumoricidal; and (iii) remodeling stroma cell and ECM.Table 3 Clinical trials targeting immune cells or stroma in PDAC

Target	Targeted therapy	Immunotherapy	Chemotherapy or radiotherapy	Phase	NCT Number	Patient population	Status/results	
Myeloid cell	GB1275 (CD11b)	Pembrolizumab (PD-1)	Gemcitabine, nab-paclitaxel	1	NCT04060342	Untreated advanced or metastatic cancers including PDAC	Terminated for no clear benefit of GB1275	
IMC-CS4 (CSF-1R)	Pembrolizumab (PD-1), GVAX	Cyclophosphamide	1	NCT03153410	Previously treated borderline resectable or locally advanced PDAC	Completed. Awaiting results	
Pexidartinib (CSF-1R)	Durvalumab (PD-L1)	N/A	1	NCT02777710	Metastatic/ advanced pancreatic or colorectal cancers	Completed. Awaiting results	
Cabiralizumab (CSF-1R)	Nivolumab (PD-1)	N/A	1	NCT02526017	Advanced or metastatic cancers including PDAC	ORR 6.0%, mOS 5.6 months, mPFS 1.7 months	
Nivolumab (PD-1)	Gemcitabine, nab-paclitaxel, FOLFOX	2	NCT03336216	Previously treated advanced or metastatic PDAC	No increase in PFS	
PF-04136309 (CCR2)	N/A	FOLFIRINOX	1/2	NCT01413022	Locally advanced or borderline resectable PDAC	49% ORR and 97% DCR compared with 0% ORR and 80% DCR in the FOLFIRINOX alone group	
N/A	Gemcitabine, nab-paclitaxel	2	NCT02732938	Untreated metastatic PDAC	Terminated	
BMS-813160 (CCR2/5)	Nivolumab (PD-1), GVAX	SBRT	1/2	NCT03767582	Untreated unresectable, locally advanced PDAC	Recruiting	
Nivolumab (PD-1)	Gemcitabine, nab-paclitaxel	1/2	NCT03496662	Locally advanced PDAC	Active. Not recruiting	
Nivolumab (PD-1)	FOLFIRI, gemcitabine, nab-paclitaxel	1/2	NCT03184870	Advanced or metastatic cancers including PDAC	Completed. Awaiting results	
AZD5069 (CXCR2)	MEDI4736 (PD-L1)	N/A	1/2	NCT02583477	Metastatic PDAC	ORR 5.6%, OS 2.8 months, PFS 1.6 months	
SX-682 (CXCR1/2)	Nivolumab (PD-1)	N/A	1	NCT04477343	Metastatic PDAC	Recruiting	
Dendritic cell	Mitazalimab (CD40)	MesoPher	N/A	1	NCT05650918	Previously treated metastatic PDAC	Completed. Awaiting results	
CDX-30 (FLT3), CDX-1140 (CD40)	N/A	N/A	2	NCT04536077	Resectable PDAC	Terminated	
Pembrolizumab (PD-1)	Gemcitabine, nab-paclitaxel	1	NCT03329950	Locally advanced or metastatic cancers including PDAC	Completed. Awaiting results	
Macrophage	CP-870,893 (CD40)	N/A	Gemcitabine	1	NCT00711191	Untreated advanced PDAC	mOS 8.4 months, mPFS 5.3 months	
APX005M (CD40)	Nivolumab (PD-1)	Gemcitabine, nab-paclitaxel	1/2	NCT03214250	Untreated metastatic PDAC	1-year OS was met for nivo/chemo but was not met for sotiga/chemo or sotiga/nivo/chemo	
NG-350A (CD40)	Ipilimumab (CTLA-4)	Gemcitabine, nab-paclitaxel	1	NCT04787991	Untreated metastatic PDAC	Active. Not recruiting	
ASTX660 (cIAP1/2)	Pembrolizumab (PD-1)	N/A	1	NCT05082259	Advanced solid tumors including PDAC	Recruiting	
SGN-CD47M (CD47)	N/A	N/A	1	NCT03957096	Solid tumors including pancreatic cancer	Terminated	
PT886 (CD47 and claudin 18.2)	N/A	N/A	1	NCT05482893	Unresectable or metastatic PDAC	Recruiting	
B cell	Ibrutinib (BTK)	N/A	Gemcitabine, nab-paclitaxel	1/2	NCT02562898	Metastatic PDAC	mOS 246 days, mPFS 128 days	
N/A	Gemcitabine, nab-paclitaxel	3	NCT02436668	Untreated metastatic PDAC	No improvement in mOS (9.7 vs 10.8 months; P = 0.3225); reduced PFS (5.3 vs 6.0 months; P = 0.0001) and ORR (29% vs 42%; P = 0.0058) compared with standard chemotherapy	
Stroma	PEGPH20 (HA)	N/A	mFOLFIRINOX	1/2	NCT01959139	Untreated metastatic PDAC	Increased toxicity; OS 7.7 months compared with 14.4 months in the mFOLFIRINOX control arm	
N/A	Gemcitabine, nab-paclitaxel	2	NCT01839487	Untreated metastatic PDAC	No improvement in ORR and OS. Moderately improved PFS	
N/A	Gemcitabine, nab-paclitaxel	3	NCT02715804	Untreated HA-high metastatic PDAC	Terminated	
Pembrolizumab (PD-1)	N/A	2	NCT03634332	Previously treated HA-High metastatic PDAC	Unknown	
Stroma	Defactinib (FAK)	Pembrolizumab (PD-1)	N/A	2	NCT03727880	Resectable PDAC	Recruiting	
N/A	1	NCT02546531	Advanced cancers including PDAC	No PR or CR observed. Increased T-cell infiltration	
N/A	1/2	NCT02758587	Advanced solid tumors including PDAC	Unknown	
Ruxolitinib (JAK-STAT)	N/A	Capecitabine	2	NCT01423604	Previously treated metastatic PDAC	Signficant improvement in OS (HR, 0.47, P = 0.011) in patients with systemic inflammation (C-reactive protein [CRP] >13mg/dL)	
N/A	Capecitabine	3	NCT02117479	Previously treated advanced or metastatic PDAC	Terminated early based on the results of the interim analysis	
N/A	Capecitabine	3	NCT02119663	Previously treated advanced or metastatic PDAC	Terminated based on a lack of efficacy in a similar trial	
Ruxolitinib (JAK-STAT), trametinib (MEK)	Retifanlimab (PD-1)	N/A	1	NCT05440942	Metastatic PDAC	Recruiting	
LY2510924 (CXCR4)	Durvalumab (PD-L1)	N/A	1	NCT02737072	Previously treated advanced cancers including PDAC	Terminated	
BMS-936564 (CXCR4)	Nivolumab (PD-1)	N/A	1/2	NCT02472977	Previously treated advanced cancers including PDAC	Terminated for lack of efficacy	
BL-8040 (CXCR4)	Pembrolizumab (PD-1)	Onivyde	2	NCT02826486	Previously treated metastatic unresectable PDAC	ORR 32%, DCR 77%, DOR 7.8 months	
N/A	2	NCT02907099	Previously treated metastatic PDAC	Completed. Awaiting results	
FLT3 fms-like tyrosine kinase 3, cIAP1/2 cellular inhibitor of apoptosis proteins 1 and 2, BTK bruton tyrosine kinase, HA hyaluronic acid, FAK focal adhesion kinase, JAK-STAT Janus kinase-signal transducer and activator of transcription, FOLFIRINOX 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, SBRT stereotactic body radiation, FOLFIRI 5-fluorouracil, leucovorin and irinotecan, MesoPher autologous monocyte-derived dendritic cells loaded with tumor lysate, mFOLFIRINOX modified FOLFIRINOX, N/A not available, ORR objective response rate, DCR disease control rate, OS overall survival, PFS progression-free survival, PR partial response, CR complete response, DOR duration of response, HR hazard ratio.

Targeting myeloid cells

The reduction of immunosuppressive myeloid cells in the TME can be achieved by blocking the chemokine-receptor axis in these cells, resulting in diminished infiltration of myeloid cells. Targeting CD11b, CSF-1R, CCR2/5, and CXCR1/2 has emerged as therapeutic strategies.

CD11b is an integrin molecule expressed on myeloid cells, playing a role in chemotaxis and cellular functions. In preclinical studies, the administration of a small-molecule agonist of CD11b led to a reduction in suppressive myeloid cell infiltration and repolarization of TAMs toward an anti-tumor phenotype, thereby eliciting a T-cell response. This treatment also showed an enhancement in the therapeutic effects of an anti-PD-1 antibody145. However, a clinical trial (NCT04060342) investigating the combination of the CD11b agonist (GB1275) with gemcitabine, nab-paclitaxel, and pembrolizumab (an anti-PD-1 antibody) was terminated due to the lack of a clear benefit in PDAC patients when GB1275 was used either as a monotherapy or in combination with pembrolizumab146.

In an orthotopic model of PDAC, blocking CSF-1R not only reduced TAM infiltration but also reprogrammed TAMs to enhance T-cell activation, resulting in increased efficacy of anti-PD-1 and anti-CTLA-4147. Unfortunately, clinical trials combining an anti-CSF-1R antibody with immunotherapy for PDAC treatment have not yielded satisfactory results thus far. For example, a phase 1a/b single-arm study combining the anti-CSF-1R antibody cabiralizumab with PD-1 blockade (nivolumab) demonstrated discouraging outcomes with an objective response rate (ORR) of 6.0%, a median overall survival (OS) of 5.6 months, and a median progression-free survival (PFS) of 1.7 months (NCT02526017)148. Moreover, a phase 2 clinical study evaluating cabiralizumab in combination with nivolumab and chemotherapy did not improve PFS in patients with advanced PDAC (NCT03336216)6,149. Currently, several ongoing trials are testing the combination of small-molecule CSF-1R inhibitors with immunotherapy in pancreatic cancer. One such trial is a dose escalation phase 1 study evaluating the safety and efficacy of a small-molecule CSF-1R inhibitor (pexidartinib) combined with an anti-PD-L1 antibody (durvalumab) in patients with metastatic/advanced pancreatic or colorectal cancer (NCT02777710)150.

Chemokine receptors, CCR2/5 and CXCR2, play a crucial role in facilitating myeloid cell infiltration into the TME43,48. Blocking these pathways has emerged as a potential strategy to overcome immunosuppression. A phase 1b trial investigating the combination of the CCR2 inhibitor PF-04136309 with FOLFIRINOX not only demonstrated safety but also yielded an ORR of 49% and a disease control rate (DCR) of 97%, surpassing the 0% ORR and 80% DCR observed in the FOLFIRINOX alone group151. However, a phase 2 trial of PF-04136309 in combination with gemcitabine and nab-paclitaxel was terminated due to toxicity and a lack of superior efficacy compared with the gemcitabine plus nab-paclitaxel group152. Several early-phase clinical trials combining BMS-813160 (a CCR2/5 dual antagonist) with ICIs and chemotherapy or vaccines are underway (Table 3). Meanwhile, targeting CXCR2 with AZD5069 in combination with an anti-PD-L1 antibody in patients with metastatic PDAC resulted in disappointing results, with an ORR of 5.6%, OS of 2.8 months, and PFS of 1.6 months (NCT02583477)153. Currently, an early-phase clinical trial investigating a CXCR1/2 dual inhibitor (SX-682) plus an anti-PD-1 antibody (nivolumab) is recruiting patients with metastatic pancreatic cancer (NCT04477343)154.

Targeting dendritic cells

Pancreatic cancer often exhibits a paucity and dysfunction of dendritic cells, which underlies poor infiltration and effector function of T cells90,155,156. Restoring dendritic cells in PDAC might enhance anti-tumor immunity. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, holds the capacity to license dendritic cells for promoting anti-tumor T-cell activation157. Several formulations of agonistic CD40 antibodies have undergone testing in preclinical and clinical settings, demonstrating tolerability and feasibility. DeNardo and colleagues156 engineered a neoantigen-expressing mouse model of PDAC and showed that enhancing dendritic cell infiltration and activity using FLT3 ligand along with an agonistic CD40 antibody resulted in increased intratumoral CD8+ cells and prolonged survival when combined with radiation therapy. Currently, early-phase clinical trials are in progress, evaluating the combination of the agonistic CD40 antibody and FLT3 ligand with anti-PD-1, gemcitabine, and nab-paclitaxel for treating pancreatic cancer and other advanced cancers (e.g., NCT03329950)158.

Dendritic cell vaccination has emerged as a strategy to enhance anti-tumor immunity159. In a syngeneic Panc02 model of pancreatic cancer, combining dendritic cell-based vaccination with gemcitabine significantly improved the survival of tumor-bearing mice compared with vaccination or gemcitabine alone160. Moreover, the combination of an allogeneic tumor lysate-loaded dendritic cell vaccine with an agonistic CD40 antibody significantly increased survival in a mouse model of pancreatic cancer, which was accompanied by an increase in CD8 + T-cell infiltration161. A recent phase 1 clinical trial involving 10 patients with resected PDAC demonstrated the safety of an allogeneic tumor lysate-loaded autologous dendritic cell vaccine, with seven out of 10 patients showing no recurrence or progression at a median follow-up of 25 months162. An ongoing phase 1 clinical trial is evaluating the safety and efficacy of a tumor lysate-loaded dendritic cell vaccine in combination with an agonistic CD40 antibody in patients with metastatic PDAC following FOLFIRINOX chemotherapy (NCT05650918)163.

Targeting B cells

BTK-dependent crosstalk between B cells and TAMs has been identified as a driver of PDAC growth. In mice bearing PDAC, the use of a BTK inhibitor (ibrutinib) led to the restoration of anti-tumor immunity, inhibition of pancreatic tumor growth, and enhanced responsiveness to standard-of-care chemotherapy65. However, a phase 3 clinical trial combining ibrutinib with gemcitabine and nab-paclitaxel failed to show improvements in PFS and overall survival in PDAC patients compared with the placebo plus gemcitabine/nab-paclitaxel cohort164. Meanwhile, the combined treatment with acalabrutinib (a second-generation BTK inhibitor) and pembrolizumab produced modest clinical benefits, with an ORR of 7.9% and a DCR of 21.1%, compared with the 0% ORR and 14.3% DCR observed in the acalabrutinib monotherapy group165.

Reprogramming macrophages

Beyond its role in activating conventional dendritic cells, CD40 activation has been found to reprogram macrophages into tumoricidal TAMs in PDAC-bearing mice115. However, in a randomized phase 2 trial involving 105 patients with PDAC, sotigalimab, an agonistic CD40 antibody, did not demonstrate survival benefits when combined with chemotherapy (gemcitabine/nab-paclitaxel) and an anti-PD-1 antibody (nivolumab)166. Currently, a phase 1 clinical trial is recruiting patients with metastatic PDAC to assess the response to gemcitabine/nab-paclitaxel in combination with the anti-CTLA-4 antibody ipilimumab plus nivolumab, hydroxychloroquine, or NG350A (a CD40 agonist) (NCT04787991)167. In addition to CD40 agonism, the cellular inhibitor of apoptosis proteins 1 and 2 (cIAP1/2) antagonist has demonstrated the induction of T-cell-dependent reprogramming of TAMs to be tumoricidal, reducing tumor burdens by enhancing phagocytosis in orthotopic models of PDAC168. A phase 1 trial evaluating the combination of the cIAP1/2 antagonist ASTX660 with the anti-PD-1 antibody pembrolizumab is recruiting patients with pancreatic cancer or other solid tumors (NCT05082259)169.

CD47 expressed on tumor cells acts as a “don’t eat me” signal by engaging signal-regulating protein alpha (SIRPα) expressed on macrophages, thereby blocking phagocytosis. This phagocytic checkpoint has gained attention as an attractive target for immunotherapy170. Given the substantial T-cell dysfunction and exhaustion observed in PDAC and other “cold” tumor types, macrophage-based therapeutic strategies have emerged to address resistance to T-cell-based immunotherapy21. A phase1/2 clinical trial is currently recruiting patients to evaluate the safety and efficacy of PT886, a bispecific antibody targeting both CD47 and claudin 18.2—a tumor antigen that is overexpressed in PDAC (NCT05482893)171.

Targeting stroma

Following encouraging preclinical studies, clinical trials focused on targeting PDAC stroma to enhance therapy responses have emerged. In preclinical models, the degradation of hyaluronan by PEGPH20 demonstrated a significant survival benefit when combined with gemcitabine77,78. In PDAC patients not selected for tumor hyaluronan status, the addition of PEGPH20 to FOLFIRINOX led to increased toxicity and a reduced median OS (7.7 months compared with 14.4 months in the FOLFIRINOX alone group)172. On the other hand, in a randomized phase 3 clinical trial involving patients with hyaluronan-high metastatic PDAC, the combination of PEGPH20 with gemcitabine/nab-paclitaxel improved the ORR but did not increase OS or PFS when compared with the placebo plus gemcitabine/nab-paclitaxel arm173. Currently, a phase 2 trial is evaluating the combination treatment with PEGPH20 and pembrolizumab in patients with hyaluronan-high metastatic PDAC (NCT03634332)174.

In a genetically engineered mouse model of PDAC, the administration of an FAK inhibitor led to a reduction of fibrosis and increased sensitivity to immunotherapy (anti-PD-1 plus anti-CTLA-4)79. A phase 1 study demonstrated that the combination of defactinib (a small-molecule inhibitor of FAK) with PD-1 blockade plus gemcitabine resulted in stable disease in 11 out of 20 patients with metastatic PDAC175; this outcome was accompanied by an increase in CD8 + T cells and a decrease in Tregs, macrophages, and stromal cells. Currently, a phase 2 trial is underway to evaluate the efficacy of pembrolizumab plus defactinib following chemotherapy as a neoadjuvant and adjuvant treatment in patients with resectable PDAC (NCT03727880)176.

CXCL12, produced by FAP+ CAFs, inhibits T-cell infiltration in pancreatic cancer. In a preclinical model of PDAC, pharmacological inhibition of CXCR4, the cognate receptor of CXCL12, enhanced the anti-tumor efficacy of PD-L1 blockade83. A phase 1 study investigated the safety and tolerability of the CXCR4 antagonist LY2510924 in combination with the anti-PD-L1 antibody durvalumab, revealing modest clinical benefits, with three out of eight patients achieving stable disease177. Of note, a recent phase 2 trial assessing the combination of BL-8040 (a CXCR4 antagonist), pembrolizumab, and Onivyde (topoisomerase I inhibitor) demonstrated encouraging results, including an ORR of 32%, a DCR of 77%, and duration of response (DOR) of 7.8 months in patients with metastatic chemotherapy-refractory PDAC178.

The JAK-STAT pathway activates pancreatic stellate cells (PSCs) and induces inflammatory CAFs, contributing to immunosuppression in PDAC81,87,179. In a phase 2 study of ruxolitinib, a small-molecule JAK1/JAK2 inhibitor, in combination with the chemotherapeutic agent capecitabine, there was no observed benefit in OS generally, but a significant increase in OS was noted in patients with systemic inflammation compared with the placebo plus capecitabine group180. Unfortunately, two subsequent randomized phase 3 studies combining ruxolitinib and capecitabine for treating advanced/metastatic pancreatic cancer showed no improvement in OS or PFS181. Currently, a phase 1 clinical trial combining ruxolitinib, retifanlimab (an anti-PD-1 antibody), and trametinib (a MEK inhibitor) is recruiting patients with metastatic PDAC (NCT05440942)182.

Discussion

Both pancreatic cancer cell-intrinsic signaling pathways and the TME play significant roles in immune suppression, contributing to the inherent resistance of pancreatic cancer to immunotherapy. Various therapeutic strategies, when combined with immunotherapy, have shown encouraging results in preclinical studies. However, the translation of these findings into clinical benefits has been challenging thus far. It is crucial to elucidate the mechanisms by which human PDAC evades immune surveillance and to devise approaches that effectively overcome immunotherapy resistance in patients. It should be noted that unrestricted cell death or tissue damage induced by chemotherapy might lead to an immunosuppressive TME183. In contrast, radiation therapy was reported to enhance the response to immunotherapy in patients with microsatellite-stable pancreatic cancer184.

Improving pancreatic cancer immunotherapy involves exploring various strategies. Some key strategies and future perspectives include: (1) combination therapies: combining different immunotherapeutic agents, including inhibitors of established and newly discovered immune checkpoints, with targeted therapies or other immunomodulators, may enhance the overall anti-tumor response. (2) Stroma-targeted approaches: targeting the dense stroma in pancreatic cancer to reduce fibrosis holds promise for improving drug delivery and enhancing immune cell infiltration. (3) Vaccine development: developing personalized cancer vaccines based on individual tumor profiles has the potential to stimulate a specific and robust immune response against cancer cells. (4) Bispecific antibodies: designing antibodies that can simultaneously target multiple antigens is likely to enhance their specificity and efficacy in engaging immune cells against cancer. (5) Adoptive cell therapies: CAR T-cell therapies, which use genetically engineered T cells directed to specific cancer-associated antigens to elicit cytotoxic activity, represent a promising therapeutic modality, although significant challenges exist for CAR T-cells to infiltrate the immunosuppressive TME of pancreatic tumors. (6) Biomarker identification: identifying reliable biomarkers to predict the response to immunotherapy will allow for better patient stratification and treatment selection. (7) Clinical trial innovation: designing innovative clinical trials to test emerging therapies and combinations can ensure a rapid translation of promising preclinical findings into clinical benefits.

These strategies are active areas of research and development, with the potential to significantly impact the future of pancreatic cancer immunotherapy. In addition, investigating strategies for early detection of pancreatic cancer will enable timely intervention, potentially improving the success of immunotherapeutic approaches.

Acknowledgements

We are grateful to members of the Yao Lab and the Ma Lab for the discussion. We thank Mr. Haoli Ma from Wuhan University Zhongnan Hospital for his support. W.B. is supported by Fundamental Research Funds for the Central Universities (2662021SYQD001). F.Y. is supported by the Hubei Provincial Natural Science Foundation (2022CFA108), the Major Project of Hubei Hongshan Laboratory (2022hszd028 and 2021hszd012), HZAU-AGIS Cooperation Fund (SZYJY2023008) and the Youth Research Project of Health Commission of Hubei Province (ZY2023Q037). L.M. is supported by US National Institutes of Health (NIH) grants R01CA166051 and R01CA269140, an American Cancer Society grant (award number: DBG-22-161-01-MM), and the Nylene Eckles Distinguished Professorship of MD Anderson Cancer Center.

Author contributions

Y.J. wrote the draft. D.X., Y.J., and M.L. made the figures and tables. Y.S., F.Y., and L.M. provided intellectual input. Y.S., W.B., F.Y., and L.M. edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Competing interests

The authors declare no competing interests. Figure 2 was created with BioRender.com.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J. Clin. 2023 73 17 48 10.3322/caac.21763 36633525
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).36633525 10.3322/caac.21763
2. Park W Chawla A O’Reilly EM Pancreatic cancer: a review JAMA 2021 326 851 862, 10.1001/jama.2021.13027 34547082
Park, W., Chawla, A. & O’Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851–862, (2021).34547082 10.1001/jama.2021.13027
3. Mizrahi JD Surana R Valle JW Shroff RT Pancreatic cancer Lancet 2020 395 2008 2020 10.1016/S0140-6736(20)30974-0 32593337
Mizrahi, J. D., Surana, R., Valle, J. W. & Shroff, R. T. Pancreatic cancer. Lancet 395, 2008–2020 (2020).32593337 10.1016/S0140-6736(20)30974-0
4. Von Hoff DD Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl. J. Med. 2013 369 1691 1703 10.1056/NEJMoa1304369 24131140
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).24131140 10.1056/NEJMoa1304369
5. Conroy T FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N. Engl. J. Med 2011 364 1817 1825 10.1056/NEJMoa1011923 21561347
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).21561347 10.1056/NEJMoa1011923
6. Ullman NA Burchard PR Dunne RF Linehan DC Immunologic strategies in pancreatic cancer: making cold tumors hot J. Clin. Oncol. 2022 40 2789 2805 10.1200/JCO.21.02616 35839445
Ullman, N. A., Burchard, P. R., Dunne, R. F. & Linehan, D. C. Immunologic strategies in pancreatic cancer: making cold tumors hot. J. Clin. Oncol. 40, 2789–2805 (2022).35839445 10.1200/JCO.21.02616
7. Kantoff PW Sipuleucel-T immunotherapy for castration-resistant prostate cancer N. Engl. J. Med. 2010 363 411 422 10.1056/NEJMoa1001294 20818862
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).20818862 10.1056/NEJMoa1001294
8. Lu J Jiang G The journey of CAR-T therapy in hematological malignancies Mol. Cancer 2022 21 194 10.1186/s12943-022-01663-0 36209106
Lu, J. & Jiang, G. The journey of CAR-T therapy in hematological malignancies. Mol. Cancer 21, 194 (2022).36209106 10.1186/s12943-022-01663-0
9. Larkin J Five-year survival with combined nivolumab and ipilimumab in advanced melanoma N. Engl. J. Med. 2019 381 1535 1546 10.1056/NEJMoa1910836 31562797
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).31562797 10.1056/NEJMoa1910836
10. Gandhi L Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N. Engl. J. Med. 2018 378 2078 2092 10.1056/NEJMoa1801005 29658856
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).29658856 10.1056/NEJMoa1801005
11. Motzer RJ Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma N. Engl. J. Med. 2018 378 1277 1290 10.1056/NEJMoa1712126 29562145
Motzer, R. J. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).29562145 10.1056/NEJMoa1712126
12. Ansell SM PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N. Engl. J. Med 2015 372 311 319 10.1056/NEJMoa1411087 25482239
Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–319 (2015).25482239 10.1056/NEJMoa1411087
13. Brahmer JR Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 2012 366 2455 2465 10.1056/NEJMoa1200694 22658128
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).22658128 10.1056/NEJMoa1200694
14. Royal RE Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma J. Immunother. 2010 33 828 833 10.1097/CJI.0b013e3181eec14c 20842054
Royal, R. E. et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828–833 (2010).20842054 10.1097/CJI.0b013e3181eec14c
15. O’Reilly EM Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial JAMA Oncol. 2019 5 1431 1438, 10.1001/jamaoncol.2019.1588 31318392
O’Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431–1438, (2019).31318392 10.1001/jamaoncol.2019.1588
16. Renouf DJ The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma Nat. Commun. 2022 13 5020 10.1038/s41467-022-32591-8 36028483
Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).36028483 10.1038/s41467-022-32591-8
17. Steele NG Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer Nat. Cancer 2020 1 1097 1112 10.1038/s43018-020-00121-4 34296197
Steele, N. G. et al. Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer. Nat. Cancer 1, 1097–1112 (2020).34296197 10.1038/s43018-020-00121-4
18. Pollini T The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms Lancet Gastroenterol. Hepatol. 2022 7 1141 1150 10.1016/S2468-1253(22)00235-7 36057265
Pollini, T. et al. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms. Lancet Gastroenterol. Hepatol. 7, 1141–1150 (2022).36057265 10.1016/S2468-1253(22)00235-7
19. Muller, M. et al. The immune landscape of human pancreatic ductal carcinoma: key players, clinical implications, and challenges. Cancers 14, 10.3390/cancers14040995 (2022).
20. Balachandran VP Beatty GL Dougan SK Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities Gastroenterology 2019 156 2056 2072 10.1053/j.gastro.2018.12.038 30660727
Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056–2072 (2019).30660727 10.1053/j.gastro.2018.12.038
21. Hosein AN Dougan SK Aguirre AJ Maitra A Translational advances in pancreatic ductal adenocarcinoma therapy Nat. Cancer 2022 3 272 286 10.1038/s43018-022-00349-2 35352061
Hosein, A. N., Dougan, S. K., Aguirre, A. J. & Maitra, A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat. Cancer 3, 272–286 (2022).35352061 10.1038/s43018-022-00349-2
22. Vonderheide RH Bear AS Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer Front. Immunol. 2020 11 605619 10.3389/fimmu.2020.605619 33304355
Vonderheide, R. H. & Bear, A. S. Tumor-derived myeloid cell chemoattractants and T cell exclusion in pancreatic cancer. Front. Immunol. 11, 605619 (2020).33304355 10.3389/fimmu.2020.605619
23. Li K Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer Signal Transduct. Target. Ther. 2021 6 362 10.1038/s41392-021-00670-9 34620838
Li, K. et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct. Target. Ther. 6, 362 (2021).34620838 10.1038/s41392-021-00670-9
24. Zhang Y Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer Gut 2017 66 124 136 10.1136/gutjnl-2016-312078 27402485
Zhang, Y. et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66, 124–136 (2017).27402485 10.1136/gutjnl-2016-312078
25. Srivastava MK Sinha P Clements VK Rodriguez P Ostrand-Rosenberg S Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Res. 2010 70 68 77 10.1158/0008-5472.CAN-09-2587 20028852
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P. & Ostrand-Rosenberg, S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70, 68–77 (2010).20028852 10.1158/0008-5472.CAN-09-2587
26. Siret C Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma Front. Immunol. 2019 10 3070 10.3389/fimmu.2019.03070 32038621
Siret, C. et al. Deciphering the crosstalk between myeloid-derived suppressor cells and regulatory T cells in pancreatic ductal adenocarcinoma. Front. Immunol. 10, 3070 (2019).32038621 10.3389/fimmu.2019.03070
27. Gabrilovich DI Ostrand-Rosenberg S Bronte V Coordinated regulation of myeloid cells by tumours Nat. Rev. Immunol. 2012 12 253 268 10.1038/nri3175 22437938
Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).22437938 10.1038/nri3175
28. Stromnes IM Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity Gut 2014 63 1769 1781 10.1136/gutjnl-2013-306271 24555999
Stromnes, I. M. et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63, 1769–1781 (2014).24555999 10.1136/gutjnl-2013-306271
29. Steele CW CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma Cancer Cell 2016 29 832 845 10.1016/j.ccell.2016.04.014 27265504
Steele, C. W. et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832–845 (2016).27265504 10.1016/j.ccell.2016.04.014
30. Gulhati P Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer Nat. Cancer 2023 4 62 80 36585453
Gulhati, P. et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat. Cancer 4, 62–80 (2023).36585453
31. Xia Q Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma Oncogene 2022 41 865 877 10.1038/s41388-021-02133-5 34862460
Xia, Q. et al. Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene 41, 865–877 (2022).34862460 10.1038/s41388-021-02133-5
32. Daley D Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance Nat. Med. 2017 23 556 567 10.1038/nm.4314 28394331
Daley, D. et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat. Med. 23, 556–567 (2017).28394331 10.1038/nm.4314
33. Kemp SB Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-κB-mediated production of CXCL1 Cancer Res. 2021 81 4305 4318 10.1158/0008-5472.CAN-20-3929 34049975
Kemp, S. B. et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-κB-mediated production of CXCL1. Cancer Res. 81, 4305–4318 (2021).34049975 10.1158/0008-5472.CAN-20-3929
34. Wang W RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer Cancer Cell 2018 34 757 774.e757 10.1016/j.ccell.2018.10.006 30423296
Wang, W. et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell 34, 757–774.e757 (2018).30423296 10.1016/j.ccell.2018.10.006
35. McAllister F Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia Cancer Cell 2014 25 621 637 10.1016/j.ccr.2014.03.014 24823639
McAllister, F. et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25, 621–637 (2014).24823639 10.1016/j.ccr.2014.03.014
36. Zhou W Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment Biomaterials 2021 268 120546 10.1016/j.biomaterials.2020.120546 33253966
Zhou, W. et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials 268, 120546 (2021).33253966 10.1016/j.biomaterials.2020.120546
37. Hou P Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer Cancer Discov. 2020 10 1058 1077 10.1158/2159-8290.CD-19-0597 32341020
Hou, P. et al. Tumor microenvironment remodeling enables bypass of oncogenic KRAS dependency in pancreatic cancer. Cancer Discov. 10, 1058–1077 (2020).32341020 10.1158/2159-8290.CD-19-0597
38. Zhang B Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer Cancer Lett. 2019 459 204 215 10.1016/j.canlet.2019.06.005 31199988
Zhang, B. et al. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Cancer Lett. 459, 204–215 (2019).31199988 10.1016/j.canlet.2019.06.005
39. Sun X Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism Gut 2022 71 129 147 10.1136/gutjnl-2020-322744 33568427
Sun, X. et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut 71, 129–147 (2022).33568427 10.1136/gutjnl-2020-322744
40. Alonso-Nocelo, M. et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut10.1136/gutjnl-2021-325564 (2022).
41. Lee BY Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis Nat. Commun. 2021 12 7336 10.1038/s41467-021-27607-8 34921158
Lee, B. Y. et al. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nat. Commun. 12, 7336 (2021).34921158 10.1038/s41467-021-27607-8
42. Blando J Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer Proc. Natl Acad. Sci. USA 2019 116 1692 1697 10.1073/pnas.1811067116 30635425
Blando, J. et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc. Natl Acad. Sci. USA 116, 1692–1697 (2019).30635425 10.1073/pnas.1811067116
43. Wang J CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma J. Exp. Med. 2022 219 e20211631 10.1084/jem.20211631 35404390
Wang, J. et al. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. J. Exp. Med. 219, e20211631 (2022).35404390 10.1084/jem.20211631
44. Wang, L. et al. Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. Gut10.1136/gutjnl-2021-326070 (2022).
45. Hester R Mazur PK McAllister F Immunotherapy in pancreatic adenocarcinoma: beyond “copy/paste Clin. Cancer Res. 2021 27 6287 6297 10.1158/1078-0432.CCR-18-0900 34193514
Hester, R., Mazur, P. K. & McAllister, F. Immunotherapy in pancreatic adenocarcinoma: beyond “copy/paste. Clin. Cancer Res. 27, 6287–6297 (2021).34193514 10.1158/1078-0432.CCR-18-0900
46. Zhang Y Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer J. Exp. Med. 2020 217 e20190354 10.1084/jem.20190354 32860704
Zhang, Y. et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J. Exp. Med. 217, e20190354 (2020).32860704 10.1084/jem.20190354
47. Nielsen SR Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade Nat. Commun. 2021 12 3414 10.1038/s41467-021-23731-7 34099731
Nielsen, S. R. et al. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nat. Commun. 12, 3414 (2021).34099731 10.1038/s41467-021-23731-7
48. Nywening TM Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma Gut 2018 67 1112 1123 10.1136/gutjnl-2017-313738 29196437
Nywening, T. M. et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67, 1112–1123 (2018).29196437 10.1136/gutjnl-2017-313738
49. Chen Q Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma J. Immunother. Cancer 2022 10 e005798 10.1136/jitc-2022-005798 36600557
Chen, Q. et al. Prognostic value of tumor-associated N1/N2 neutrophil plasticity in patients following radical resection of pancreas ductal adenocarcinoma. J. Immunother. Cancer 10, e005798 (2022).36600557 10.1136/jitc-2022-005798
50. Peng H Local release of TGF-β inhibitor modulates tumor-associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy Adv. Sci. 2022 9 e2105240 10.1002/advs.202105240
Peng, H. et al. Local release of TGF-β inhibitor modulates tumor-associated neutrophils and enhances pancreatic cancer response to combined irreversible electroporation and immunotherapy. Adv. Sci. 9, e2105240 (2022).10.1002/advs.202105240
51. Ma Y Hwang RF Logsdon CD Ullrich SE Dynamic mast cell–stromal cell interactions promote growth of pancreatic cancer Cancer Res. 2013 73 3927 3937 10.1158/0008-5472.CAN-12-4479 23633481
Ma, Y., Hwang, R. F., Logsdon, C. D. & Ullrich, S. E. Dynamic mast cell–stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 73, 3927–3937 (2013).23633481 10.1158/0008-5472.CAN-12-4479
52. Chang DZ Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma Clin. Cancer Res. 2011 17 7015 7023 10.1158/1078-0432.CCR-11-0607 21976550
Chang, D. Z. et al. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 17, 7015–7023 (2011).21976550 10.1158/1078-0432.CCR-11-0607
53. Strouch MJ Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression Clin. Cancer Res. 2010 16 2257 2265 10.1158/1078-0432.CCR-09-1230 20371681
Strouch, M. J. et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin. Cancer Res. 16, 2257–2265 (2010).20371681 10.1158/1078-0432.CCR-09-1230
54. Shi S Ye L Yu X Jin K Wu W Focus on mast cells in the tumor microenvironment: Current knowledge and future directions Biochim. Biophys. Acta Rev. Cancer 2023 1878 188845 10.1016/j.bbcan.2022.188845 36476563
Shi, S., Ye, L., Yu, X., Jin, K. & Wu, W. Focus on mast cells in the tumor microenvironment: Current knowledge and future directions. Biochim. Biophys. Acta Rev. Cancer 1878, 188845 (2023).36476563 10.1016/j.bbcan.2022.188845
55. Somasundaram R Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy Nat. Commun. 2021 12 346 10.1038/s41467-020-20600-7 33436641
Somasundaram, R. et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat. Commun. 12, 346 (2021).33436641 10.1038/s41467-020-20600-7
56. Stromnes IM Hulbert A Pierce RH Greenberg PD Hingorani SR T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma Cancer Immunol. Res. 2017 5 978 991 10.1158/2326-6066.CIR-16-0322 29066497
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D. & Hingorani, S. R. T-cell localization, activation, and clonal expansion in human pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 5, 978–991 (2017).29066497 10.1158/2326-6066.CIR-16-0322
57. Tang Y An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma PLoS One 2014 9 e91551 10.1371/journal.pone.0091551 24637664
Tang, Y. et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 9, e91551 (2014).24637664 10.1371/journal.pone.0091551
58. Hiraoka N Onozato K Kosuge T Hirohashi S Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions Clin. Cancer Res. 2006 12 5423 5434 10.1158/1078-0432.CCR-06-0369 17000676
Hiraoka, N., Onozato, K., Kosuge, T. & Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423–5434 (2006).17000676 10.1158/1078-0432.CCR-06-0369
59. Sakaguchi S Regulatory T cells and human disease Annu. Rev. Immunol. 2020 38 541 566 10.1146/annurev-immunol-042718-041717 32017635
Sakaguchi, S. et al. Regulatory T cells and human disease. Annu. Rev. Immunol. 38, 541–566 (2020).32017635 10.1146/annurev-immunol-042718-041717
60. Zou W Regulatory T cells, tumour immunity and immunotherapy Nat. Rev. Immunol. 2006 6 295 307 10.1038/nri1806 16557261
Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295–307 (2006).16557261 10.1038/nri1806
61. Jang J-E Crosstalk between regulatory T Cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer Cell Rep. 2017 20 558 571 10.1016/j.celrep.2017.06.062 28723561
Jang, J.-E. et al. Crosstalk between regulatory T Cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 20, 558–571 (2017).28723561 10.1016/j.celrep.2017.06.062
62. Zhang Y Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis Cancer Discov. 2020 10 422 439 10.1158/2159-8290.CD-19-0958 31911451
Zhang, Y. et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 10, 422–439 (2020).31911451 10.1158/2159-8290.CD-19-0958
63. Mirlekar B Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity Cell Rep. Med. 2022 3 100744 10.1016/j.xcrm.2022.100744 36099917
Mirlekar, B. et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep. Med. 3, 100744 (2022).36099917 10.1016/j.xcrm.2022.100744
64. Das S Bar-Sagi D BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis Oncogene 2019 38 3316 3324 10.1038/s41388-018-0668-3 30635655
Das, S. & Bar-Sagi, D. BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis. Oncogene 38, 3316–3324 (2019).30635655 10.1038/s41388-018-0668-3
65. Gunderson AJ Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer Cancer Discov. 2016 6 270 285 10.1158/2159-8290.CD-15-0827 26715645
Gunderson, A. J. et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 6, 270–285 (2016).26715645 10.1158/2159-8290.CD-15-0827
66. Li S STING-induced regulatory B cells compromise NK function in cancer immunity Nature 2022 610 373 380 10.1038/s41586-022-05254-3 36198789
Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373–380 (2022).36198789 10.1038/s41586-022-05254-3
67. Takahashi R Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression Gut 2021 70 330 341 32393543
Takahashi, R. et al. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Gut 70, 330–341 (2021).32393543
68. Michaud D Mirlekar B Steward C Bishop G Pylayeva-Gupta Y B cell receptor signaling and protein kinase D2 support regulatory B cell function in pancreatic cancer Front. Immunol. 2021 12 745873 10.3389/fimmu.2021.745873 35046933
Michaud, D., Mirlekar, B., Steward, C., Bishop, G. & Pylayeva-Gupta, Y. B cell receptor signaling and protein kinase D2 support regulatory B cell function in pancreatic cancer. Front. Immunol. 12, 745873 (2021).35046933 10.3389/fimmu.2021.745873
69. Mirlekar B B cell-derived IL35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic cancer Cancer Immunol. Res. 2020 8 292 308 10.1158/2326-6066.CIR-19-0349 32024640
Mirlekar, B. et al. B cell-derived IL35 drives STAT3-dependent CD8+ T-cell exclusion in pancreatic cancer. Cancer Immunol. Res. 8, 292–308 (2020).32024640 10.1158/2326-6066.CIR-19-0349
70. Lee KE Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia Cancer Discov. 2016 6 256 269 10.1158/2159-8290.CD-15-0822 26715642
Lee, K. E. et al. Hif1a deletion reveals pro-neoplastic function of B cells in pancreatic neoplasia. Cancer Discov. 6, 256–269 (2016).26715642 10.1158/2159-8290.CD-15-0822
71. Zhao Y Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway Oncotarget 2018 9 14803 14814 10.18632/oncotarget.22976 29599908
Zhao, Y. et al. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Oncotarget 9, 14803–14814 (2018).29599908 10.18632/oncotarget.22976
72. Chen Y-I Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation Nat. Commun. 2022 13 2945 10.1038/s41467-022-30638-4 35618735
Chen, Y.-I. et al. Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation. Nat. Commun. 13, 2945 (2022).35618735 10.1038/s41467-022-30638-4
73. Öhlund D Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer J. Exp. Med. 2017 214 579 596 10.1084/jem.20162024 28232471
Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).28232471 10.1084/jem.20162024
74. Hosein AN Brekken RA Maitra A Pancreatic cancer stroma: an update on therapeutic targeting strategies Nat. Rev. Gastroenterol. Hepatol. 2020 17 487 505 10.1038/s41575-020-0300-1 32393771
Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487–505 (2020).32393771 10.1038/s41575-020-0300-1
75. LaRue MM Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer Proc. Natl Acad. Sci. USA 2022 119 e2119168119 10.1073/pnas.2119168119 35412885
LaRue, M. M. et al. Metabolic reprogramming of tumor-associated macrophages by collagen turnover promotes fibrosis in pancreatic cancer. Proc. Natl Acad. Sci. USA 119, e2119168119 (2022).35412885 10.1073/pnas.2119168119
76. Zhao J Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer ACS Nano 2018 12 9881 9893 10.1021/acsnano.8b02481 30231203
Zhao, J. et al. Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer. ACS Nano 12, 9881–9893 (2018).30231203 10.1021/acsnano.8b02481
77. Jacobetz MA Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer Gut 2013 62 112 120 10.1136/gutjnl-2012-302529 22466618
Jacobetz, M. A. et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 62, 112–120 (2013).22466618 10.1136/gutjnl-2012-302529
78. Provenzano PP Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma Cancer Cell 2012 21 418 429 10.1016/j.ccr.2012.01.007 22439937
Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).22439937 10.1016/j.ccr.2012.01.007
79. Jiang H Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy Nat. Med. 2016 22 851 860 10.1038/nm.4123 27376576
Jiang, H. et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851–860 (2016).27376576 10.1038/nm.4123
80. Blair AB Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-programmed cell death protein 1 therapy Gastroenterology 2022 163 1267 1280.e1267 10.1053/j.gastro.2022.06.027 35718227
Blair, A. B. et al. Dual stromal targeting sensitizes pancreatic adenocarcinoma for anti-programmed cell death protein 1 therapy. Gastroenterology 163, 1267–1280.e1267 (2022).35718227 10.1053/j.gastro.2022.06.027
81. Mace TA Bloomston M Lesinski GB Pancreatic cancer-associated stellate cells: a viable target for reducing immunosuppression in the tumor microenvironment Oncoimmunology 2013 2 e24891 10.4161/onci.24891 24073373
Mace, T. A., Bloomston, M. & Lesinski, G. B. Pancreatic cancer-associated stellate cells: a viable target for reducing immunosuppression in the tumor microenvironment. Oncoimmunology 2, e24891 (2013).24073373 10.4161/onci.24891
82. Liu H Shi Y Qian F Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts Adv. Drug Deliv. Rev. 2021 172 37 51 10.1016/j.addr.2021.02.012 33705881
Liu, H., Shi, Y. & Qian, F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv. Drug Deliv. Rev. 172, 37–51 (2021).33705881 10.1016/j.addr.2021.02.012
83. Feig C Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer Proc. Natl Acad. Sci. USA 2013 110 20212 20217 10.1073/pnas.1320318110 24277834
Feig, C. et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl Acad. Sci. USA 110, 20212–20217 (2013).24277834 10.1073/pnas.1320318110
84. McAndrews KM Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer Cancer Discov. 2022 12 1580 1597 10.1158/2159-8290.CD-20-1484 35348629
McAndrews, K. M. et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 12, 1580–1597 (2022).35348629 10.1158/2159-8290.CD-20-1484
85. Özdemir BC Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival Cancer Cell 2014 25 719 734 10.1016/j.ccr.2014.04.005 24856586
Özdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719–734 (2014).24856586 10.1016/j.ccr.2014.04.005
86. Elyada E Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts Cancer Discov. 2019 9 1102 1123 10.1158/2159-8290.CD-19-0094 31197017
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).31197017 10.1158/2159-8290.CD-19-0094
87. Biffi G IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma Cancer Discov. 2019 9 282 301 10.1158/2159-8290.CD-18-0710 30366930
Biffi, G. et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282–301 (2019).30366930 10.1158/2159-8290.CD-18-0710
88. Helms EJ Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts Cancer Discov. 2022 12 484 501 10.1158/2159-8290.CD-21-0601 34548310
Helms, E. J. et al. Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts. Cancer Discov. 12, 484–501 (2022).34548310 10.1158/2159-8290.CD-21-0601
89. Huang H Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer Cancer Cell 2022 40 656 673.e657 10.1016/j.ccell.2022.04.011 35523176
Huang, H. et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 40, 656–673.e657 (2022).35523176 10.1016/j.ccell.2022.04.011
90. Lin JH Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis J. Exp. Med. 2020 217 e20190673 10.1084/jem.20190673 32453421
Lin, J. H. et al. Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. J. Exp. Med. 217, e20190673 (2020).32453421 10.1084/jem.20190673
91. Flint TR Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity Cell Metab. 2016 24 672 684 10.1016/j.cmet.2016.10.010 27829137
Flint, T. R. et al. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 24, 672–684 (2016).27829137 10.1016/j.cmet.2016.10.010
92. Picard FSR IL-17A-producing CD8(+) T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts Gut 2023 72 1510 1522 10.1136/gutjnl-2022-327855 36759154
Picard, F. S. R. et al. IL-17A-producing CD8(+) T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Gut 72, 1510–1522 (2023).36759154 10.1136/gutjnl-2022-327855
93. Chen Y Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer Cancer Cell 2021 39 548 565.e546 10.1016/j.ccell.2021.02.007 33667385
Chen, Y. et al. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Cancer Cell 39, 548–565.e546 (2021).33667385 10.1016/j.ccell.2021.02.007
94. Su H Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome Nature 2022 610 366 372 10.1038/s41586-022-05169-z 36198801
Su, H. et al. Collagenolysis-dependent DDR1 signalling dictates pancreatic cancer outcome. Nature 610, 366–372 (2022).36198801 10.1038/s41586-022-05169-z
95. Datta J Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer Gastroenterology 2022 163 1593 1612 10.1053/j.gastro.2022.07.076 35948109
Datta, J. et al. Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer. Gastroenterology 163, 1593–1612 (2022).35948109 10.1053/j.gastro.2022.07.076
96. Aykut B The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL Nature 2019 574 264 267 10.1038/s41586-019-1608-2 31578522
Aykut, B. et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature 574, 264–267 (2019).31578522 10.1038/s41586-019-1608-2
97. Pushalkar S The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression Cancer Discov. 2018 8 403 416 10.1158/2159-8290.CD-17-1134 29567829
Pushalkar, S. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8, 403–416 (2018).29567829 10.1158/2159-8290.CD-17-1134
98. Riquelme E Tumor microbiome diversity and composition influence pancreatic cancer outcomes Cell 2019 178 795 806.e712 10.1016/j.cell.2019.07.008 31398337
Riquelme, E. et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178, 795–806.e712 (2019).31398337 10.1016/j.cell.2019.07.008
99. Sethi V Gut microbiota promotes tumor growth in mice by modulating immune response Gastroenterology 2018 155 33 37.e36 10.1053/j.gastro.2018.04.001 29630898
Sethi, V. et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 155, 33–37.e36 (2018).29630898 10.1053/j.gastro.2018.04.001
100. Alam A Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer Cancer Cell 2022 40 153 167.e111 10.1016/j.ccell.2022.01.003 35120601
Alam, A. et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell 40, 153–167.e111 (2022).35120601 10.1016/j.ccell.2022.01.003
101. Hezaveh K Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity Immunity 2022 55 324 340.e328 10.1016/j.immuni.2022.01.006 35139353
Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324–340.e328 (2022).35139353 10.1016/j.immuni.2022.01.006
102. Mirji G The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer Sci. Immunol. 2022 7 eabn0704 10.1126/sciimmunol.abn0704 36083892
Mirji, G. et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci. Immunol. 7, eabn0704 (2022).36083892 10.1126/sciimmunol.abn0704
103. Nagata N Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study Gastroenterology 2022 163 222 238 10.1053/j.gastro.2022.03.054 35398347
Nagata, N. et al. Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study. Gastroenterology 163, 222–238 (2022).35398347 10.1053/j.gastro.2022.03.054
104. Gihawi A Major data analysis errors invalidate cancer microbiome findings mBio 2023 14 e0160723 10.1128/mbio.01607-23 37811944
Gihawi, A. et al. Major data analysis errors invalidate cancer microbiome findings. mBio 14, e0160723 (2023).37811944 10.1128/mbio.01607-23
105. Ho WJ Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways Genome Biol. 2021 22 154 10.1186/s13059-021-02363-6 33985562
Ho, W. J. et al. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol. 22, 154 (2021).33985562 10.1186/s13059-021-02363-6
106. Karamitopoulou E Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer Gut 2023 72 1523 1533 10.1136/gutjnl-2022-329371 36792355
Karamitopoulou, E. et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut 72, 1523–1533 (2023).36792355 10.1136/gutjnl-2022-329371
107. Wang X Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis Nat. Commun. 2021 12 174 10.1038/s41467-020-20447-y 33420030
Wang, X. et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat. Commun. 12, 174 (2021).33420030 10.1038/s41467-020-20447-y
108. Astuti Y Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis Nat. Cancer 2024 5 774 790 10.1038/s43018-024-00731-2 38355776
Astuti, Y. et al. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Nat. Cancer 5, 774–790 (2024).38355776 10.1038/s43018-024-00731-2
109. Raymant M Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer Nat. Commun. 2024 15 3593 10.1038/s41467-024-47949-3 38678021
Raymant, M. et al. Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Nat. Commun. 15, 3593 (2024).38678021 10.1038/s41467-024-47949-3
110. Pham, T. N. D. et al. Preclinical models of pancreatic ductal adenocarcinoma and their utility in immunotherapy studies. Cancers 13, 10.3390/cancers13030440 (2021).
111. Mallya K Gautam SK Aithal A Batra SK Jain M Modeling pancreatic cancer in mice for experimental therapeutics Biochim. Biophys. Acta Rev. Cancer 2021 1876 188554 10.1016/j.bbcan.2021.188554 33945847
Mallya, K., Gautam, S. K., Aithal, A., Batra, S. K. & Jain, M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim. Biophys. Acta Rev. Cancer 1876, 188554 (2021).33945847 10.1016/j.bbcan.2021.188554
112. Jung, J. Y. et al. siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth in humanized preclinical model. Cells 10, 10.3390/cells10102734 (2021).
113. Pan Y Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer J. Hematol. Oncol. 2019 12 124 10.1186/s13045-019-0822-6 31771616
Pan, Y. et al. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. J. Hematol. Oncol. 12, 124 (2019).31771616 10.1186/s13045-019-0822-6
114. Vonderheide RH CD40 immunotherapy for pancreatic cancer Cancer Immunol. Immunother. 2013 62 949 954 10.1007/s00262-013-1427-5 23589109
Vonderheide, R. H. et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunol. Immunother. 62, 949–954 (2013).23589109 10.1007/s00262-013-1427-5
115. Beatty GL CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 2011 331 1612 1616 10.1126/science.1198443 21436454
Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612–1616 (2011).21436454 10.1126/science.1198443
116. Kerk SA Papagiannakopoulos T Shah YM Lyssiotis CA Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment Nat. Rev. Cancer 2021 21 510 525 10.1038/s41568-021-00375-9 34244683
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M. & Lyssiotis, C. A. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat. Rev. Cancer 21, 510–525 (2021).34244683 10.1038/s41568-021-00375-9
117. Buscail L Bournet B Cordelier P Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. 2020 17 153 168 10.1038/s41575-019-0245-4 32005945
Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153–168 (2020).32005945 10.1038/s41575-019-0245-4
118. Chao T Furth EE Vonderheide RH CXCR2-dependent accumulation of tumor-associated neutrophils regulates t-cell immunity in pancreatic ductal adenocarcinoma Cancer Immunol. Res. 2016 4 968 982 10.1158/2326-6066.CIR-16-0188 27737879
Chao, T., Furth, E. E. & Vonderheide, R. H. CXCR2-dependent accumulation of tumor-associated neutrophils regulates t-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 4, 968–982 (2016).27737879 10.1158/2326-6066.CIR-16-0188
119. Pylayeva-Gupta Y Lee KE Hajdu CH Miller G Bar-Sagi D Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia Cancer Cell 2012 21 836 847 10.1016/j.ccr.2012.04.024 22698407
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836–847 (2012).22698407 10.1016/j.ccr.2012.04.024
120. Coelho MA Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA Immunity 2017 47 1083 1099.e1086 10.1016/j.immuni.2017.11.016 29246442
Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083–1099.e1086 (2017).29246442 10.1016/j.immuni.2017.11.016
121. Hu Y K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis Cell Res. 2012 22 399 412 10.1038/cr.2011.145 21876558
Hu, Y. et al. K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Res. 22, 399–412 (2012).21876558 10.1038/cr.2011.145
122. Glorieux C Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling Redox Biol. 2021 38 101780 10.1016/j.redox.2020.101780 33171331
Glorieux, C. et al. Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling. Redox Biol. 38, 101780 (2021).33171331 10.1016/j.redox.2020.101780
123. Collins MA Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice J. Clin. Investig. 2012 122 639 653 10.1172/JCI59227 22232209
Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Investig. 122, 639–653 (2012).22232209 10.1172/JCI59227
124. Jones S Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 2008 321 1801 1806 10.1126/science.1164368 18772397
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801–1806 (2008).18772397 10.1126/science.1164368
125. Zeng G Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma Neoplasia 2006 8 279 289 10.1593/neo.05607 16756720
Zeng, G. et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8, 279–289 (2006).16756720 10.1593/neo.05607
126. Aguilera KY Dawson DW WNT ligand dependencies in pancreatic cancer Front. Cell Dev. Biol. 2021 9 671022 10.3389/fcell.2021.671022 33996827
Aguilera, K. Y. & Dawson, D. W. WNT ligand dependencies in pancreatic cancer. Front. Cell Dev. Biol. 9, 671022 (2021).33996827 10.3389/fcell.2021.671022
127. Jiang X Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma Proc. Natl Acad. Sci. USA 2013 110 12649 12654 10.1073/pnas.1307218110 23847203
Jiang, X. et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA 110, 12649–12654 (2013).23847203 10.1073/pnas.1307218110
128. Hosein AN Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma Gastroenterology 2022 162 1303 1318.e1318 10.1053/j.gastro.2021.12.273 34973294
Hosein, A. N. et al. Loss of Rnf43 accelerates Kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma. Gastroenterology 162, 1303–1318.e1318 (2022).34973294 10.1053/j.gastro.2021.12.273
129. Zhou M LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation J. Exp. Clin. Cancer Res. 2022 41 288 10.1186/s13046-022-02491-2 36171592
Zhou, M. et al. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. J. Exp. Clin. Cancer Res. 41, 288 (2022).36171592 10.1186/s13046-022-02491-2
130. Chen Y Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer Cancer Cell 2022 40 818 834.e819 10.1016/j.ccell.2022.06.011 35868307
Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 40, 818–834.e819 (2022).35868307 10.1016/j.ccell.2022.06.011
131. Galluzzi L Spranger S Fuchs E López-Soto A WNT signaling in cancer immunosurveillance Trends Cell Biol. 2019 29 44 65 10.1016/j.tcb.2018.08.005 30220580
Galluzzi, L., Spranger, S., Fuchs, E. & López-Soto, A. WNT signaling in cancer immunosurveillance. Trends Cell Biol. 29, 44–65 (2019).30220580 10.1016/j.tcb.2018.08.005
132. Yamamoto K Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I Nature 2020 581 100 105 10.1038/s41586-020-2229-5 32376951
Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100–105 (2020).32376951 10.1038/s41586-020-2229-5
133. Cheung PF Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression Nat. Commun. 2022 13 156 10.1038/s41467-021-27088-9 35013174
Cheung, P. F. et al. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nat. Commun. 13, 156 (2022).35013174 10.1038/s41467-021-27088-9
134. Cain DW Cidlowski JA Immune regulation by glucocorticoids Nat. Rev. Immunol. 2017 17 233 247 10.1038/nri.2017.1 28192415
Cain, D. W. & Cidlowski, J. A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 17, 233–247 (2017).28192415 10.1038/nri.2017.1
135. Deng Y Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance Nat. Commun. 2021 12 7041 10.1038/s41467-021-27349-7 34873175
Deng, Y. et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat. Commun. 12, 7041 (2021).34873175 10.1038/s41467-021-27349-7
136. Wang B Niu D Lai L Ren EC p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1 Nat. Commun. 2013 4 2359 10.1038/ncomms3359 23965983
Wang, B., Niu, D., Lai, L. & Ren, E. C. p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat. Commun. 4, 2359 (2013).23965983 10.1038/ncomms3359
137. Zhu K p53 induces TAP1 and enhances the transport of MHC class I peptides Oncogene 1999 18 7740 7747 10.1038/sj.onc.1203235 10618714
Zhu, K. et al. p53 induces TAP1 and enhances the transport of MHC class I peptides. Oncogene 18, 7740–7747 (1999).10618714 10.1038/sj.onc.1203235
138. Abrego J A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity Cancer Discov. 2022 12 2414 2433 10.1158/2159-8290.CD-22-0661 35894778
Abrego, J. et al. A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity. Cancer Discov. 12, 2414–2433 (2022).35894778 10.1158/2159-8290.CD-22-0661
139. Liu J QDPR deficiency drives immune suppression in pancreatic cancer Cell Metab. 2024 36 984 999.e988 10.1016/j.cmet.2024.03.015 38642552
Liu, J. et al. QDPR deficiency drives immune suppression in pancreatic cancer. Cell Metab. 36, 984–999.e988 (2024).38642552 10.1016/j.cmet.2024.03.015
140. He C Vitamin B6 competition in the tumor microenvironment hampers antitumor functions of NK cells Cancer Discov. 2024 14 176 193 10.1158/2159-8290.CD-23-0334 37931287
He, C. et al. Vitamin B6 competition in the tumor microenvironment hampers antitumor functions of NK cells. Cancer Discov. 14, 176–193 (2024).37931287 10.1158/2159-8290.CD-23-0334
141. Zhu XG Functional genomics in vivo reveal metabolic dependencies of pancreatic cancer cells Cell Metab. 2021 33 211 221.e216 10.1016/j.cmet.2020.10.017 33152324
Zhu, X. G. et al. Functional genomics in vivo reveal metabolic dependencies of pancreatic cancer cells. Cell Metab. 33, 211–221.e216 (2021).33152324 10.1016/j.cmet.2020.10.017
142. Niu N Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer Cancer Cell 2024 42 869 884.e869 10.1016/j.ccell.2024.03.005 38579725
Niu, N. et al. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell 42, 869–884.e869 (2024).38579725 10.1016/j.ccell.2024.03.005
143. Niu N Tumor cell-intrinsic SETD2 deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis Adv. Sci. 2023 10 e2202937 10.1002/advs.202202937
Niu, N. et al. Tumor cell-intrinsic SETD2 deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis. Adv. Sci. 10, e2202937 (2023).10.1002/advs.202202937
144. Mills BN Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy Clin. Cancer Res. 2022 28 150 162 10.1158/1078-0432.CCR-21-2495 34862242
Mills, B. N. et al. Modulation of the human pancreatic ductal adenocarcinoma immune microenvironment by stereotactic body radiotherapy. Clin. Cancer Res. 28, 150–162 (2022).34862242 10.1158/1078-0432.CCR-21-2495
145. Panni RZ Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies Sci. Transl. Med. 2019 11 eaau9240 10.1126/scitranslmed.aau9240 31270275
Panni, R. Z. et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci. Transl. Med. 11, eaau9240 (2019).31270275 10.1126/scitranslmed.aau9240
146. GB006 Inc. (a wholly owned subsidiary of Gossamer Bio, Inc.) & Merck Sharp & Dohme LLC. A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors. Report No. NCT04060342 (clinicaltrials.gov, 2022).
147. Zhu Y CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models Cancer Res. 2014 74 5057 5069 10.1158/0008-5472.CAN-13-3723 25082815
Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057–5069 (2014).25082815 10.1158/0008-5472.CAN-13-3723
148. Five Prime Therapeutics, I. A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers. Report No. NCT02526017, (clinicaltrials.gov, 2022).
149. Squibb, B.-M. A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer. Report No. study/NCT03336216, (clinicaltrials.gov, 2022).
150. Berard, C. L. A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers. Report No. NCT02777710, (clinicaltrials.gov, 2021).
151. Nywening TM Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial Lancet Oncol. 2016 17 651 662 10.1016/S1470-2045(16)00078-4 27055731
Nywening, T. M. et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 17, 651–662 (2016).27055731 10.1016/S1470-2045(16)00078-4
152. Noel M Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma Invest. N. Drugs 2020 38 800 811 10.1007/s10637-019-00830-3
Noel, M. et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest. N. Drugs 38, 800–811 (2020).10.1007/s10637-019-00830-3
153. AstraZeneca. A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Report No. NCT02583477 (clinicaltrials.gov, 2019).
154. Mulkerin, D. An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Report No. NCT04477343 (clinicaltrials.gov, 2022).
155. Meyer MA Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance Nat. Commun. 2018 9 1250 10.1038/s41467-018-03600-6 29593283
Meyer, M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat. Commun. 9, 1250 (2018).29593283 10.1038/s41467-018-03600-6
156. Hegde S Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer Cancer Cell 2020 37 289 307.e289 10.1016/j.ccell.2020.02.008 32183949
Hegde, S. et al. Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer. Cancer Cell 37, 289–307.e289 (2020).32183949 10.1016/j.ccell.2020.02.008
157. Vonderheide RH CD40 agonist antibodies in cancer immunotherapy Annu. Rev. Med. 2020 71 47 58 10.1146/annurev-med-062518-045435 31412220
Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47–58 (2020).31412220 10.1146/annurev-med-062518-045435
158. Therapeutics, C. A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies. Report No. NCT03329950, (clinicaltrials.gov, 2022).
159. Harari A Graciotti M Bassani-Sternberg M Kandalaft LE Antitumour dendritic cell vaccination in a priming and boosting approach Nat. Rev. Drug Discov. 2020 19 635 652 10.1038/s41573-020-0074-8 32764681
Harari, A., Graciotti, M., Bassani-Sternberg, M. & Kandalaft, L. E. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat. Rev. Drug Discov. 19, 635–652 (2020).32764681 10.1038/s41573-020-0074-8
160. Bauer C Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut 2007 56 1275 1282 10.1136/gut.2006.108621 17395611
Bauer, C. et al. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut 56, 1275–1282 (2007).17395611 10.1136/gut.2006.108621
161. Lau, S. P. et al. Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model. J. Immunother. Cancer 8, 10.1136/jitc-2020-000772 (2020).
162. Lau SP Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study Eur. J. Cancer 2022 169 20 31 10.1016/j.ejca.2022.03.015 35490565
Lau, S. P. et al. Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: a phase I study. Eur. J. Cancer 169, 20–31 (2022).35490565 10.1016/j.ejca.2022.03.015
163. Aerts, J. Dendritic Cells Loaded With Allogeneic Tumor Lysate (MesoPher) in Combination With a CD40 Agonist (Mitazalimab) in Metastatic Pancreatic Disease. Report No. study/NCT05650918 (clinicaltrials.gov, 2022). https://clinicaltrials.gov/study/NCT05650918?term=NCT05650918&rank=1#collaborators-andinvestigators.
164. Tempero M Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study Ann. Oncol. 2021 32 600 608 10.1016/j.annonc.2021.01.070 33539945
Tempero, M. et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann. Oncol. 32, 600–608 (2021).33539945 10.1016/j.annonc.2021.01.070
165. Overman, M. et al. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J. Immunother. Cancer 8, 10.1136/jitc-2020-000587 (2020).
166. Padrón LJ Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Nat. Med. 2022 28 1167 1177 10.1038/s41591-022-01829-9 35662283
Padrón, L. J. et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167–1177 (2022).35662283 10.1038/s41591-022-01829-9
167. Immunotherapy, P. I. f. C. A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated Metastatic Pancreatic AdenOcarciNoma (REVOLUTION). Report No. NCT04787991 (clinicaltrials.gov, 2023).
168. Roehle K cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes Sci. Transl. Med. 2021 13 eabf5058 10.1126/scitranslmed.abf5058 34011631
Roehle, K. et al. cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes. Sci. Transl. Med. 13, eabf5058 (2021).34011631 10.1126/scitranslmed.abf5058
169. Institute of Cancer Research, U. K. ASTEROID: A Phase I Trial of ASTX660 in Combination With Pembrolizumab in Patients With Solid Tumours: Utilizing Triple IAP Blockade as a Strategy to Maximize Immunogenic Cell Death and the Generation of an Efficient Adaptive Immune Response. Report No. NCT05082259 (clinicaltrials.gov, 2022).
170. Feng M Phagocytosis checkpoints as new targets for cancer immunotherapy Nat. Rev. Cancer 2019 19 568 586 10.1038/s41568-019-0183-z 31462760
Feng, M. et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568–586 (2019).31462760 10.1038/s41568-019-0183-z
171. Therapeutics, P. A Phase I, First-in-Human, Open-Label, Dose Escalation and Expansion Study of PT886 in Adult Patients With Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas. Report No. NCT05482893 (clinicaltrials.gov, 2022).
172. Ramanathan RK Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313 J. Clin. Oncol. 2019 37 1062 1069 10.1200/JCO.18.01295 30817250
Ramanathan, R. K. et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J. Clin. Oncol. 37, 1062–1069 (2019).30817250 10.1200/JCO.18.01295
173. Van Cutsem E Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma J. Clin. Oncol. 2020 38 3185 3194 10.1200/JCO.20.00590 32706635
Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185–3194 (2020).32706635 10.1200/JCO.20.00590
174. Team, P. C. R. Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma. Report No. NCT03634332, (clinicaltrials.gov, 2019).
175. Wang-Gillam A Abstract CT118: phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients Cancer Res. 2020 80 CT118 10.1158/1538-7445.AM2020-CT118
Wang-Gillam, A. et al. Abstract CT118: phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer: Experiences of pancreatic ductal adenocarcinoma (PDAC) patients. Cancer Res. 80, CT118 (2020).10.1158/1538-7445.AM2020-CT118
176. Hopkins, S. K. C. C. C. A. J. A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC). Report No. NCT03727880 (clinicaltrials.gov, 2022).
177. O’Hara MH Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors J. Pancreat. Cancer 2020 6 21 31 10.1089/pancan.2019.0018 32219196
O’Hara, M. H. et al. Safety and pharmacokinetics of CXCR4 peptide antagonist, LY2510924, in combination with durvalumab in advanced refractory solid tumors. J. Pancreat. Cancer 6, 21–31 (2020).32219196 10.1089/pancan.2019.0018
178. Bockorny B BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial Nat. Med. 2020 26 878 885 10.1038/s41591-020-0880-x 32451495
Bockorny, B. et al. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat. Med. 26, 878–885 (2020).32451495 10.1038/s41591-020-0880-x
179. Komar HM Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo Sci. Rep. 2017 7 1787 10.1038/s41598-017-01973-0 28496202
Komar, H. M. et al. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci. Rep. 7, 1787 (2017).28496202 10.1038/s41598-017-01973-0
180. Hurwitz HI Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed J. Clin. Oncol. 2015 33 4039 4047 10.1200/JCO.2015.61.4578 26351344
Hurwitz, H. I. et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J. Clin. Oncol. 33, 4039–4047 (2015).26351344 10.1200/JCO.2015.61.4578
181. Hurwitz H Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies Invest. N. Drugs 2018 36 683 695 10.1007/s10637-018-0580-2
Hurwitz, H. et al. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest. N. Drugs 36, 683–695 (2018).10.1007/s10637-018-0580-2
182. Hosein, P., Incyte Corporation, Novartis Pharmaceuticals & University of Miami Sylvester Comprehensive Cancer Center. A Phase 1 Trial of Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma. Report No. NCT05440942 (clinicaltrials.gov, 2023).
183. Chen X Zeh HJ Kang R Kroemer G Tang D Cell death in pancreatic cancer: from pathogenesis to therapy Nat. Rev. Gastroenterol. Hepatol. 2021 18 804 823 10.1038/s41575-021-00486-6 34331036
Chen, X., Zeh, H. J., Kang, R., Kroemer, G. & Tang, D. Cell death in pancreatic cancer: from pathogenesis to therapy. Nat. Rev. Gastroenterol. Hepatol. 18, 804–823 (2021).34331036 10.1038/s41575-021-00486-6
184. Parikh AR Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial Nat. Cancer 2021 2 1124 1135 10.1038/s43018-021-00269-7 35122060
Parikh, A. R. et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat. Cancer 2, 1124–1135 (2021).35122060 10.1038/s43018-021-00269-7
